[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"KCI USA, INC.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":409},{"warningLetters":4,"total":408},[5,31,50,70,95,113,133,151,172,194,216,236,257,275,294,312,335,355,372,390],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3288,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-06-29T13:20:00Z\">06\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-21T04:00:00Z\">06\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fidc-usa-inc-613966-06212021\">IDC USA INC\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hu Liu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>IDC USA INC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6619 18th Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11204-4315\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 613966\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 21, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hu Liu:\u003C\u002Fp>\n\n\u003Cp>On December 3, 2020, through February 24, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of IDC USA Inc. located at 6619 18th Ave Brooklyn, NY 11204. We also conducted an inspection on February 26, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your dried longan and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that during the most recent inspection you stated that you are \u003Cstrong>(b)(4)\u003C\u002Fstrong> and you provided our investigator with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, private laboratory analysis for shipments of dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates and dried longan imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a supplier evaluation questionnaire completed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a document stating that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a qualified supplier from January 2020 through December 2021 dated January 15, 2020, and written assurances from some of your foreign suppliers, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, stating that their processes and procedures provide at least the same level of public health protection as FDA food safety regulations. However, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> you provided show that your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on February 26, 2019, and the follow-up inspection on February 24, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. We received your response to the initial inspection on March 10, 2019, which included documents related to dried mushrooms imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates and herbal tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The documents included a “Supplier Evaluation Questionnaire” for \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as the hazard analysis and Hazard Analysis Critical Control Point (HACCP) plan for dried shrimp and dried shellfish imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and the hazard analysis and HACCP plan for dried mushroom (dried fungus) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided analytical reports for entries of dried mushroom, dried shrimp, and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates. We acknowledged your response on September 6, 2019 and provided you some additional guidance. In general, these documents could be used as part of your FSVP, but you did not document your review and assessment of these documents. To date, we have not received your response to the Form FDA 483a issued on February 24, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for your dried longan and dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. You did not conduct a written hazard analysis for your dried fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. We note that you may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505) and conduct foreign supplier verification activities (21 CFR 1.506), among other requirements. With respect to your evaluation of a foreign supplier’s performance, you may rely on another entity’s evaluation, but that entity may not be the foreign supplier themselves, and you must document your review and assessment of the evaluation, as required under 21 CFR 1.505(d). In addition, you provided private laboratory analysis for shipments of dried \u003Cstrong>(b)(4)\u003C\u002Fstrong> dates imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and dried longan imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. While sampling and testing of a food may be an appropriate supplier verification activity, the testing should be specific to the hazards being controlled, among other requirements (21 CFR 1.506).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import these products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 613966 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Anna Alexander\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Hu Liu\n\nRecipient Title\n\nPresident\n\nIDC USA INC\n\n6619 18th Ave\n\nBrooklyn, NY 11204-4315\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nCMS # 613966\n\nJune 21, 2021\n\nDear Mr. Hu Liu:\n\nOn December 3, 2020, through February 24, 2021, the Food and Drug Administration conducted a remote Foreign Supplier Verification Program (FSVP) inspection of IDC USA Inc. located at 6619 18th Ave Brooklyn, NY 11204. We also conducted an inspection on February 26, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for your dried longan and dried (b)(4) dates imported from (b)(4) located in (b)(4) and dried fungus imported from (b)(4) in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nWe acknowledge that during the most recent inspection you stated that you are (b)(4) and you provided our investigator with (b)(4), private laboratory analysis for shipments of dried (b)(4) dates and dried longan imported from (b)(4), a supplier evaluation questionnaire completed by (b)(4), a document stating that (b)(4) is a qualified supplier from January 2020 through December 2021 dated January 15, 2020, and written assurances from some of your foreign suppliers, including (b)(4), stating that their processes and procedures provide at least the same level of public health protection as FDA food safety regulations. However, the (b)(4) you provided show that your firm (b)(4).\n\nAt the conclusion of both the initial FSVP inspection on February 26, 2019, and the follow-up inspection on February 24, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations. We received your response to the initial inspection on March 10, 2019, which included documents related to dried mushrooms imported from (b)(4) located in (b)(4) and dried (b)(4) dates and herbal tea imported from (b)(4) located in (b)(4). The documents included a “Supplier Evaluation Questionnaire” for (b)(4) and (b)(4), as well as the hazard analysis and Hazard Analysis Critical Control Point (HACCP) plan for dried shrimp and dried shellfish imported from (b)(4) and the hazard analysis and HACCP plan for dried mushroom (dried fungus) imported from (b)(4). You also provided analytical reports for entries of dried mushroom, dried shrimp, and dried (b)(4) dates. We acknowledged your response on September 6, 2019 and provided you some additional guidance. In general, these documents could be used as part of your FSVP, but you did not document your review and assessment of these documents. To date, we have not received your response to the Form FDA 483a issued on February 24, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for your dried longan and dried (b)(4) dates imported from (b)(4) located in (b)(4).\n\n2. You did not conduct a written hazard analysis for your dried fungus imported from (b)(4) located in (b)(4) to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. We note that you may meet your requirement to conduct a hazard analysis, as required under 21 CFR 1.504(a), by reviewing and assessing your supplier’s hazard analysis and documenting your review and assessment of that hazard analysis (21 CFR 1.504(d)). The FSVP regulation also generally requires that you evaluate your foreign supplier’s performance (21 CFR 1.505) and conduct foreign supplier verification activities (21 CFR 1.506), among other requirements. With respect to your evaluation of a foreign supplier’s performance, you may rely on another entity’s evaluation, but that entity may not be the foreign supplier themselves, and you must document your review and assessment of the evaluation, as required under 21 CFR 1.505(d). In addition, you provided private laboratory analysis for shipments of dried (b)(4) dates imported from (b)(4) and dried longan imported from (b)(4). While sampling and testing of a food may be an appropriate supplier verification activity, the testing should be specific to the hazards being controlled, among other requirements (21 CFR 1.506).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import these products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Linda Ross, FDA Compliance Officer; Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) linda.ross@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ross via email at linda.ross@fda.hhs.gov. Please reference CMS # 613966 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnna Alexander\n\nActing Program Division Director\n\nDivision of Northeast Imports","IDC USA INC","idc-usa-inc-613966-06212021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fidc-usa-inc-613966-06212021","2026-10-26T08:08:57.279135+00:00","Warning Letter","Issued","2021-06-29","613966","Food & Beverages","Mr. Hu Liu","2026-08-20T03:02:45.492+00:00","VIA UNITED PARCEL SERVICE","2021-06-21",{"id":32,"raw":33,"subject":12,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":18,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":46,"body_fetched_at":47,"delivery_method":48,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},3361,[34,35,36,37,12,13,13,13],"\u003Ctime datetime=\"2021-05-11T13:20:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-30T04:00:00Z\">04\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021\">J &amp; L USA Inc.\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sam Sanwei Liang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>J &amp; L USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6541 E Washington Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-1821\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 30, 2021\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 613754\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liang:\u003C\u002Fp>\n\n\u003Cp>On January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J &amp; L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\u003C\u002Fp>\n\n\u003Cp>a. Green Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nb. Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nc. Dried White Fungus imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nd. Rock Candy imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\ne. Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Dried White Fungus imported from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>; and Rock Candy and Brown Candy in Pieces imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawton W. Lum\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSam Sanwei Liang\n\nRecipient Title\n\nGeneral Manager\n\nJ & L USA Inc.\n\n6541 E Washington Boulevard\n\nCommerce, CA 90040-1821\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nApril 30, 2021\n\nRe: CMS # 613754\n\nDear Mr. Liang:\n\nOn January 19, 2021, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of FSVP records that you submitted to FDA electronically for your firm J & L USA Inc., located at 6541 E Washington Blvd., Commerce, CA 90040-1821. We also conducted an inspection on May 31, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the Foreign Supplier Verification Program (FSVP) implementing regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring our inspections, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4). Additionally, we found that you are still not in compliance with the requirements of 21 CFR Part 1 subpart L for the Rock Candy and Brown Candy in Pieces imported from (b)(4) from the previous inspection. Your firm did not have FSVPs for these food products. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial FSVP inspection on May 31, 2019 and the current inspection on January 19, 2021, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to either Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, your firm did not develop an FSVP for each of the following foods:\n\na. Green Tea imported from (b)(4), located in (b)(4)\n\nb. Dried Bamboo Leaf imported from (b)(4), located in (b)(4)\n\nc. Dried White Fungus imported from (b)(4), located in (b)(4)\n\nd. Rock Candy imported from (b)(4), located in (b)(4)\n\ne. Brown Candy in Pieces imported from (b)(4), located in (b)(4)\n\nThe above violation is not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter adequately may lead to regulatory action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of Green Tea and Dried Bamboo Leaf imported from (b)(4); Dried White Fungus imported from (b)(4); and Rock Candy and Brown Candy in Pieces imported from (b)(4) that appear to be in violation of section 805. We may place these foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to address any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #613754 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nLawton W. Lum\n\nActing Program Division Director\n\nDivision of West Coast Imports","J & L USA Inc.","j-l-usa-inc-613754-04302021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fj-l-usa-inc-613754-04302021","2026-10-26T08:09:02.006209+00:00","2021-05-11","613754","Sam Sanwei Liang","2026-08-20T03:08:54.946+00:00","United Parcel Service","2021-04-30",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":19,"body_fetched_at":68,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},1041,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2025-03-04T05:00:00Z\">03\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-25T05:00:00Z\">02\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-usa-698435-02252025\">TKTX USA\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>TKTX USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@tktxusa.com\"> admin@tktxusa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 25, 2025\u003C\u002Fp>\u003Cp>RE: 698435\u003C\u002Fp>\u003Cp>Dear Sir\u002FMadam:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s distribution of the drug products “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” “TKTX Gold Numbing Cream 40%,” and “TKTX Yellow Numbing Cream 40%” (hereinafter collectively referred to as “TKTX Numbing Creams”) for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxusa.com, where your products are available for purchase in the United States without a prescription. We also reviewed your social media handles, “TKTX Numbing Cream USA” on Facebook and “tktx.numbingcream” on Instagram, which direct consumers to your website to purchase the products.\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). “TKTX Numbing Creams” are also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d).\u003C\u002Fp>\u003Cp>Your firm markets the above listed drug products as external analgesics to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, laser cosmetic procedures, microblading, and others. These products are marketed without an approved application under section 505 of the FD&amp;C Act for indications that are not included in a final administrative order issued under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform to the conditions of marketing in the external analgesics final administrative order issued under section 505G.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and a recent news release\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003Cbr>Examples from the “TKTX Numbing Creams” product labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Blue Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“\u003Cstrong>What is TKTX Blue Numbing Cream?\u003C\u002Fstrong> Blue TKTX Numbing Cream is a topical anesthetic designed to numb the skin surface, effectively reducing pain and discomfort associated with dermal procedures. It is widely used in various cosmetic and medical applications to provide temporary relief from pain and itching.” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Ingredients of TKTX Blue Numbing Cream\u003C\u002Fstrong> The primary ingredients typically found in Blue TKTX Numbing Cream include: ∙Lidocaine: An anesthetic that numbs tissue in a specific area. ∙Prilocaine: Another anesthetic that works in conjunction with Lidocaine to increase numbness. ∙ Epinephrine: Helps to reduce bleeding and prolong the duration of the anesthetic effect…” [from the product website]\u003C\u002Fp>\u003Cp>“Blue TKTX Numbing Cream is used during: ∙Tattoo application and removal. ∙Body piercing. ∙Cosmetic procedures like microblading and lip fillers. ∙Laser hair removal and other laser treatments. ∙Minor surgical procedures and injections…To use Blue TKTX Numbing Cream…2. Apply a generous amount of cream to the skin and spread it evenly. 3. Cover the area with a plastic wrap to enhance absorption. 4. Leave the cream on the skin for approximately 25 to 30 minutes before the procedure. 5. Remove the wrap and wipe away any excess cream before starting the procedure.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Green Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“\u003Cstrong>What is TKTX Green Numbing Cream 40%?\u003C\u002Fstrong> TKTX Green Numbing Cream 40% is a topical anesthetic with a potent formula designed to numb the skin effectively. The “40%” indicates the strength of active agents in the cream, which is formulated to provide maximum pain relief for skin procedures that may otherwise be quite painful.” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Ingredients of Green TKTX Numbing Cream\u003C\u002Fstrong> The Green TKTX Numbing Cream is composed of several active ingredients, which may include: ∙Lidocaine: A local anesthetic that helps to reduce pain and discomfort. ∙Prilocaine: Another anesthetic that increases the numbing effect when combined with Lidocaine. ∙Epinephrine: Helps to prolong the numbing effect and decrease bleeding and swelling…” [from the product website]\u003C\u002Fp>\u003Cp>“Green TKTX Numbing Cream is commonly used for: Tattoo application, especially in areas with dense nerve endings. ∙Body piercing procedures. ∙Cosmetic procedures such as microblading and dermal fillers. ∙Laser hair removal and other laser-based skin treatments. ∙Minor surgical procedures that can be performed without deep anesthesia…” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Numbing Cream Variants\u003C\u002Fstrong> TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are: ∙ Green: This variant has a 40% concentration of lidocaine and is recommended for use on sensitive areas such as the face, neck, and genitals…” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Black Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Black Numbing Cream 40%\u003C\u002Fstrong> Introducing the powerful TKTX Black Numbing Cream, a trusted ally in pain management since its inception. Specially formulated for maximum efficiency, this cream is an ideal solution for easing discomfort associated with a wide range of skin procedures such as tattoos, cosmetic treatments, and laser hair removal. Recognized for its exceptional quality, TKTX Black sets the standard in pain relief, providing a numbing effect that lasts for a full four hours when applied correctly.” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Numbing Cream Variants\u003C\u002Fstrong> TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are…∙ Black: The black variant contains 25% lidocaine and is ideal for use on smaller areas, such as the fingers and toes…” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Gold Numbing Cream 40%\u003C\u002Fu>”\u003C\u002Fp>\u003Cp>“\u003Cstrong>What is TKTX Gold Numbing Cream 40%?\u003C\u002Fstrong> Gold TKTX Numbing Cream 40% is a highly concentrated topical anesthetic cream that provides significant numbing effects for skin procedures. The “40%” indicates a potent blend of active ingredients designed to deliver an intense level of numbness for an extended period of time, making it suitable for more painful procedures where deep numbing is essential.” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Ingredients of TKTX Gold Numbing Cream\u003C\u002Fstrong> The key ingredients in Gold TKTX Numbing Cream usually include: ∙Lidocaine: A numbing agent that provides pain relief by blocking nerve signals in the skin. ∙Prilocaine: Works synergistically with Lidocaine to enhance the numbing effect. ∙Epinephrine: Constricts blood vessels to reduce swelling and bleeding, and prolongs the duration of the anesthetic.” [from the product website]\u003C\u002Fp>\u003Cp>“Gold TKTX Numbing Cream is typically utilized for: ∙Extensive tattooing sessions. ∙Piercings in sensitive areas. ∙Cosmetic procedures that may cause significant discomfort, such as deep laser treatments and extensive waxing. ∙Minor surgical interventions that do not require injectable anesthesia….” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Numbing Cream Variants\u003C\u002Fstrong> TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are… ∙Gold: This variant has the lowest concentration of lidocaine at 20% and is recommended for use on thicker skin, such as the palms and soles of the feet.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Yellow Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Yellow Numbing Cream 40%\u003C\u002Fstrong> …This cream, known for its authentic quality, skillfully alleviates pain and discomfort linked to various skin procedures, including cosmetic treatments, tattoo applications, and laser hair removal. With a standing as a top choice in the realm of pain relief, its effectiveness and quality are evident. When applied as directed, it maintains its numbing effect for up to 04 hours.” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>TKTX Numbing Cream Variants\u003C\u002Fstrong> TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are…∙Yellow: With a 35% concentration of lidocaine, this variant is suitable for use on larger areas of the body, such as the arms and legs…” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence “TKTX Numbing Creams” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX Numbing Creams” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesics monograph”).\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “TKTX Numbing Creams” do not conform to the conditions of use specified in the external analgesics monograph for the reasons described below.\u003C\u002Fp>\u003Cp>The combinations and\u002For concentrations for the active ingredients identified in the labeling for the “TKTX Numbing Creams” do not conform to the conditions of use set forth in M017. Specifically, your labeling purports that “TKTX Green Numbing Cream 40%,” “TKTX Yellow Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” and “TKTX Gold Numbing Cream 40%” have a concentration of lidocaine at 40%, 35%, 25%, and 20%, respectively. These concentrations are above the 0.5% to 4% concentration range of lidocaine permitted in M017. Additionally, these drug products also include lidocaine in combination with other active ingredients that are not permitted in M017. As noted above, your labeling states that “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” and “TKTX Gold Numbing Cream 40%,” are typically composed of lidocaine, prilocaine, and epinephrine. Neither epinephrine nor prilocaine are permitted as active ingredients in M017. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>Furthermore, labeling for all of the “TKTX Numbing Creams” include indications that are not consistent with the indications for external analgesic drug products. Claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic or surgical procedures are not included in M017 or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\u003C\u002Fp>\u003Cp>Thus, “TKTX Numbing Creams” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without and approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” “TKTX Gold Numbing Cream 40%,” and “TKTX Yellow Numbing Cream 40%” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nTKTX USA\n\nUnited States\n\nadmin@tktxusa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 25, 2025\nRE: 698435\nDear Sir\u002FMadam:\nThis letter concerns your firm’s distribution of the drug products “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” “TKTX Gold Numbing Cream 40%,” and “TKTX Yellow Numbing Cream 40%” (hereinafter collectively referred to as “TKTX Numbing Creams”) for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxusa.com, where your products are available for purchase in the United States without a prescription. We also reviewed your social media handles, “TKTX Numbing Cream USA” on Facebook and “tktx.numbingcream” on Instagram, which direct consumers to your website to purchase the products.\n“TKTX Numbing Creams” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). “TKTX Numbing Creams” are also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d).\nYour firm markets the above listed drug products as external analgesics to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, laser cosmetic procedures, microblading, and others. These products are marketed without an approved application under section 505 of the FD&C Act for indications that are not included in a final administrative order issued under section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform to the conditions of marketing in the external analgesics final administrative order issued under section 505G.1\nFDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories2 and a recent news release3 about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\nUnapproved New Drug and Misbranded Drug Violations\n“TKTX Numbing Creams” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “TKTX Numbing Creams” product labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\n“TKTX Blue Numbing Cream 40%”\n“What is TKTX Blue Numbing Cream? Blue TKTX Numbing Cream is a topical anesthetic designed to numb the skin surface, effectively reducing pain and discomfort associated with dermal procedures. It is widely used in various cosmetic and medical applications to provide temporary relief from pain and itching.” [from the product website]\n“Ingredients of TKTX Blue Numbing Cream The primary ingredients typically found in Blue TKTX Numbing Cream include: ∙Lidocaine: An anesthetic that numbs tissue in a specific area. ∙Prilocaine: Another anesthetic that works in conjunction with Lidocaine to increase numbness. ∙ Epinephrine: Helps to reduce bleeding and prolong the duration of the anesthetic effect…” [from the product website]\n“Blue TKTX Numbing Cream is used during: ∙Tattoo application and removal. ∙Body piercing. ∙Cosmetic procedures like microblading and lip fillers. ∙Laser hair removal and other laser treatments. ∙Minor surgical procedures and injections…To use Blue TKTX Numbing Cream…2. Apply a generous amount of cream to the skin and spread it evenly. 3. Cover the area with a plastic wrap to enhance absorption. 4. Leave the cream on the skin for approximately 25 to 30 minutes before the procedure. 5. Remove the wrap and wipe away any excess cream before starting the procedure.” [from the product website]\n“TKTX Green Numbing Cream 40%”\n“What is TKTX Green Numbing Cream 40%? TKTX Green Numbing Cream 40% is a topical anesthetic with a potent formula designed to numb the skin effectively. The “40%” indicates the strength of active agents in the cream, which is formulated to provide maximum pain relief for skin procedures that may otherwise be quite painful.” [from the product website]\n“Ingredients of Green TKTX Numbing Cream The Green TKTX Numbing Cream is composed of several active ingredients, which may include: ∙Lidocaine: A local anesthetic that helps to reduce pain and discomfort. ∙Prilocaine: Another anesthetic that increases the numbing effect when combined with Lidocaine. ∙Epinephrine: Helps to prolong the numbing effect and decrease bleeding and swelling…” [from the product website]\n“Green TKTX Numbing Cream is commonly used for: Tattoo application, especially in areas with dense nerve endings. ∙Body piercing procedures. ∙Cosmetic procedures such as microblading and dermal fillers. ∙Laser hair removal and other laser-based skin treatments. ∙Minor surgical procedures that can be performed without deep anesthesia…” [from the product website]\n“TKTX Numbing Cream Variants TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are: ∙ Green: This variant has a 40% concentration of lidocaine and is recommended for use on sensitive areas such as the face, neck, and genitals…” [from the product website]\n“TKTX Black Numbing Cream 40%”\n“TKTX Black Numbing Cream 40% Introducing the powerful TKTX Black Numbing Cream, a trusted ally in pain management since its inception. Specially formulated for maximum efficiency, this cream is an ideal solution for easing discomfort associated with a wide range of skin procedures such as tattoos, cosmetic treatments, and laser hair removal. Recognized for its exceptional quality, TKTX Black sets the standard in pain relief, providing a numbing effect that lasts for a full four hours when applied correctly.” [from the product website]\n“TKTX Numbing Cream Variants TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are…∙ Black: The black variant contains 25% lidocaine and is ideal for use on smaller areas, such as the fingers and toes…” [from the product website]\n“TKTX Gold Numbing Cream 40%”\n“What is TKTX Gold Numbing Cream 40%? Gold TKTX Numbing Cream 40% is a highly concentrated topical anesthetic cream that provides significant numbing effects for skin procedures. The “40%” indicates a potent blend of active ingredients designed to deliver an intense level of numbness for an extended period of time, making it suitable for more painful procedures where deep numbing is essential.” [from the product website]\n“Ingredients of TKTX Gold Numbing Cream The key ingredients in Gold TKTX Numbing Cream usually include: ∙Lidocaine: A numbing agent that provides pain relief by blocking nerve signals in the skin. ∙Prilocaine: Works synergistically with Lidocaine to enhance the numbing effect. ∙Epinephrine: Constricts blood vessels to reduce swelling and bleeding, and prolongs the duration of the anesthetic.” [from the product website]\n“Gold TKTX Numbing Cream is typically utilized for: ∙Extensive tattooing sessions. ∙Piercings in sensitive areas. ∙Cosmetic procedures that may cause significant discomfort, such as deep laser treatments and extensive waxing. ∙Minor surgical interventions that do not require injectable anesthesia….” [from the product website]\n“TKTX Numbing Cream Variants TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are… ∙Gold: This variant has the lowest concentration of lidocaine at 20% and is recommended for use on thicker skin, such as the palms and soles of the feet.” [from the product website]\n“TKTX Yellow Numbing Cream 40%”\n“TKTX Yellow Numbing Cream 40% …This cream, known for its authentic quality, skillfully alleviates pain and discomfort linked to various skin procedures, including cosmetic treatments, tattoo applications, and laser hair removal. With a standing as a top choice in the realm of pain relief, its effectiveness and quality are evident. When applied as directed, it maintains its numbing effect for up to 04 hours.” [from the product website]\n“TKTX Numbing Cream Variants TKTX Numbing Cream comes in four different variants, each with its unique color and potency level. They are…∙Yellow: With a 35% concentration of lidocaine, this variant is suitable for use on larger areas of the body, such as the arms and legs…” [from the product website]\nUnapproved New Drug Violations\nBased on the above labeling evidence “TKTX Numbing Creams” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX Numbing Creams” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesics monograph”).4 However, “TKTX Numbing Creams” do not conform to the conditions of use specified in the external analgesics monograph for the reasons described below.\nThe combinations and\u002For concentrations for the active ingredients identified in the labeling for the “TKTX Numbing Creams” do not conform to the conditions of use set forth in M017. Specifically, your labeling purports that “TKTX Green Numbing Cream 40%,” “TKTX Yellow Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” and “TKTX Gold Numbing Cream 40%” have a concentration of lidocaine at 40%, 35%, 25%, and 20%, respectively. These concentrations are above the 0.5% to 4% concentration range of lidocaine permitted in M017. Additionally, these drug products also include lidocaine in combination with other active ingredients that are not permitted in M017. As noted above, your labeling states that “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” and “TKTX Gold Numbing Cream 40%,” are typically composed of lidocaine, prilocaine, and epinephrine. Neither epinephrine nor prilocaine are permitted as active ingredients in M017. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\nFurthermore, labeling for all of the “TKTX Numbing Creams” include indications that are not consistent with the indications for external analgesic drug products. Claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic or surgical procedures are not included in M017 or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\nThus, “TKTX Numbing Creams” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.5 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without and approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nMisbranded Drug Violations\n“TKTX Numbing Creams” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________\n1 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n2 Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\n3 Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health\n4 M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n5 FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “TKTX Blue Numbing Cream 40%,” “TKTX Green Numbing Cream 40%,” “TKTX Black Numbing Cream 40%,” “TKTX Gold Numbing Cream 40%,” and “TKTX Yellow Numbing Cream 40%” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.","TKTX USA","tktx-usa-698435-02252025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-usa-698435-02252025","2026-10-26T08:10:13.174393+00:00","2025-03-04","698435","Drugs Over-the-Counter Drugs","2026-08-19T17:00:26.345+00:00","2025-02-25",{"id":71,"raw":72,"subject":77,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":86,"posted_date":87,"marcs_cms_no":88,"product_type":26,"closeout_date":89,"issuing_office":90,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1513,[73,74,75,76,77,13,78,13],"\u003Ctime datetime=\"2024-04-16T13:20:00Z\">04\u002F16\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-22T05:00:00Z\">11\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-11222023\">Euro USA Inc\u003C\u002Fa>"," Division of Human and Animal Food Operations East V","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-09172024\">\u003Ctime datetime=\"2024-09-23T04:00:00Z\">09\u002F23\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph O’Donnell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Euro USA Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4481 Johnston Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cleveland\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44128\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 666173\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2023\u003C\u002Fp>\n\n\u003Cp>Mr. Joseph O’Donnell, Chief Executive Officer\u003Cbr>\nEuro USA, Inc.\u003Cbr>\n4481 Johnston Parkway\u003Cbr>\nCleveland, Ohio 44128\u003C\u002Fp>\n\n\u003Cp>Dear Mr. O’Donnell:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4481 Johnston Parkway, Cleveland Ohio from July 10 to July 25, 2023. We found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123, and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fish and fishery products are adulterated, in that they have been prepared, packed, or held under insanitary conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards &amp; Controls Guidance through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483, Inspectional Observations. You provided a written response to the inspection on August 11, 2023, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your HACCP program.\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s HACCP plans for Combined Molluscan Shellfish that includes your shucked, raw scallops in cans, Pasteurized Crabmeat and Scombroid Fish lists critical limits that are inadequate to control the hazards of Clostridium botulinum, pathogenic growth and toxin formation and histamine formation.\u003C\u002Fp>\n\n\u003Cp>a. At the storage critical control point for your Combined Molluscan Shellfish, which includes reduced oxygen packaged shucked raw scallops in cans, the listed critical limit is “Storage cooler temperature not to exceed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, a critical limit of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is necessary to control C. botulinum growth and toxin formation\u003C\u002Fp>\n\n\u003Cp>b. At the storage critical control point for your Pasteurized Crabmeat HACCP, the listed critical limit of “Storage cooler temperature should not exceed \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for over \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, many of the cooler temperatures exceeded this critical limit in June and July 2023. Most notably, the temperature range was \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;from July 2-8, 2023. In addition, your critical limit should ensure the products are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, our investigator reviewed your continuous monitoring system (CMS) records for your seafood storage cooler. The CMS data records from May 20 to July 10, 2023, revealed your seafood storage cooler temperatures ranged from \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for entire days. Additionally, employees used infrared thermometer (IR) guns to monitor the same storage cooler temperatures and for the same time span, the IR temperature recordings were logged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>c. The receiving CCP for your Combined Molluscan Shellfish HACCP plan that includes your reduced oxygen packaged shucked raw, scallops in cans, lists a critical limit that fails to ensure the products were held at adequate temperatures continuously during transit to your facility \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>d. The receiving CCP for your Scombroid fish HACCP plan, lists a critical limit that is not adequate to control histamine formation. The critical limit indicates you may receive scombroid fish with gel packs. If so, FDA recommends internal temperatures of a representative number of fish be taken at receiving. Your written response indicated that you are revising your HACCP plans to reflect the correct CCP, and seafood staff have been trained on new procedures. We find your response inadequate in that you did not provide evidence\u002Fdocumentation to demonstrate your corrective actions or that employee training was performed.\u003C\u002Fp>\n\n\u003Cp>2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b), (c)(4). However, your firm did not follow monitoring and verification procedures for your Combined Molluscan Shellfish, Scombroid Fish and Pasteurized Crabmeat HACCP plans. Specifically,\u003C\u002Fp>\n\n\u003Cp>a. The monitoring procedure at the storage critical control point (CCP) for your Scombroid fish lists checking the adequacy of ice “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. However, your firm operates \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to your Daily Seafood Sanitation Reports on June 3, 6, 13, 17, 18, 20, 24, and 25, 2023 and July 4, 8, and 9, 2023, the adequacy of ice was \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On June 11 and July 1-3, 2023, the adequacy of ice was not checked at all. Furthermore, the monitoring procedures don’t include taking the internal temperatures of fish to ensure the critical limit is met. The monitoring procedures don’t require a representative number of containers to be examined and the approximate number of containers in the cooler.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that your HACCP plans are under review and will be revised. Additionally, your response indicated that employees were trained on proper monitoring procedures; however, a new HACCP plan hasn’t been implemented yet, nor was evidence provided to document employee training was performed. This response is inadequate in that corrective actions have not been taken or implemented. You also failed to offer a timeframe on when these revisions would be completed.\u003C\u002Fp>\n\n\u003Cp>3. You must take appropriate corrective actions when a deviation from a critical limit occurs, to comply with 21 CFR 123.7(a). However, your corrective actions were not appropriate to control your hazards of pathogenic bacteria growth, toxin formation and \u003Cem>C. botulinum\u003C\u002Fem> toxin formation when your cooler temperatures for the storage of Pasteurized Crabmeat and your shucked shellfish meat deviated from your listed critical limits of “Storage cooler temperature should not exceed \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for over \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “Storge cooler temperature not to exceed&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, respectively.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your trained Seafood HACCP employee reviewed your CMS records that revealed critical limit deviations and failed to evaluate the product or conduct any type of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that employees were trained on the importance of performing necessary corrective actions; however, you failed to provide evidence that employee training was performed.\u003C\u002Fp>\n\n\u003Cp>4. Your HACCP plans include corrective action plans that are not in accordance with 21 CFR 123.7(b) to ensure affected product is not entered into commerce and the cause of the deviation was corrected as required by 21 CFR 123.6(c)(5). Specifically,\u003C\u002Fp>\n\n\u003Cp>a. The CCP of cooler storage of fresh shucked shellfish meat for you Combined Molluscan Shellfish and Pasteurized Crabmeat HACCP plans are inadequate to control Clostridium botulinum growth and toxin formation. Your HACCP plans do not list corrective actions on evaluating the cumulative time and the ambient cooler temperature exposures of the affected product, rejecting the lot or diverting to a non-food use.\u003C\u002Fp>\n\n\u003Cp>b. The CCP’s of receiving and Finished Product Storage in the Scombroid Fish HACCP plan are inadequate to control histamine formation. Taking the internal product temperature alone at receiving does not control the hazard. Additionally, waiting until the finished product storage cooler temperature is above \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for more than \u003Cstrong>(b)(4)\u003C\u002Fstrong>, checking the adequacy of ice and product temperature does not control the hazard. Furthermore, the HACCP plan doesn’t document chilling, holding, rejecting or diverting the lot to non-food use.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that your HACCP plans are under review. This response is inadequate in that corrective actions have not been taken or implemented. Additionally, you failed to offer a timeframe on when these revisions would be completed.\u003C\u002Fp>\n\n\u003Cp>5. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs) to comply with 21 CFR 123.11 (b). However, your firm did not monitor for the adequacy of key areas of sanitation \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>on June 3, 9, 13, 17, 18, 20, 24, 25 and July 4, 8 and 9, 2023. Additionally, you failed to check the adequacy of any key areas of sanitation at all on June 11 and July 1-3, 2023.\u003C\u002Fp>\n\n\u003Cp>Your written response indicated that employees were trained to check and record sanitation conditions and practices \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>per shift; however, you failed to provide evidence that employee training was performed or adequately completed “Daily Seafood CCP and Sanitation Report” forms.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Please send your reply to the Food and Drug Administration, Attention: Allison Hunter, Compliance Officer, 550 Main Street, Suite 4-930, Cincinnati, Ohio 45202. If you prefer to send your response electronically, please email it to ORAHAFEAST5FirmResponses@fda.hhs.gov. If you have any questions regarding this letter, please contact Allison C. Hunter, Compliance Officer, at Allison.hunter@fda.hhs.gov or (513) 322-0629.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph O’Donnell\n\nRecipient Title\n\nChief Executive Officer\n\nEuro USA Inc\n\n4481 Johnston Parkway\n\nCleveland, OH 44128\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER 666173\n\nNovember 22, 2023\n\nMr. Joseph O’Donnell, Chief Executive Officer\n\nEuro USA, Inc.\n\n4481 Johnston Parkway\n\nCleveland, Ohio 44128\n\nDear Mr. O’Donnell:\n\nThe United States Food and Drug Administration (FDA) inspected your seafood processing facility located at 4481 Johnston Parkway, Cleveland Ohio from July 10 to July 25, 2023. We found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123, and the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fish and fishery products are adulterated, in that they have been prepared, packed, or held under insanitary conditions whereby it may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the Fish and Fisheries Products Hazards & Controls Guidance through links in FDA's home page at www.fda.gov.\n\nAt the conclusion of the inspection, the FDA investigator issued your facility a Form FDA 483, Inspectional Observations. You provided a written response to the inspection on August 11, 2023, which included corrective actions taken by your firm. We have reviewed the documentation and continue to have serious concerns with your HACCP program.\n\nYour significant deviations are as follows:\n\n1. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as \"the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.\" However, your firm’s HACCP plans for Combined Molluscan Shellfish that includes your shucked, raw scallops in cans, Pasteurized Crabmeat and Scombroid Fish lists critical limits that are inadequate to control the hazards of Clostridium botulinum, pathogenic growth and toxin formation and histamine formation.\n\na. At the storage critical control point for your Combined Molluscan Shellfish, which includes reduced oxygen packaged shucked raw scallops in cans, the listed critical limit is “Storage cooler temperature not to exceed (b)(4). However, a critical limit of (b)(4) is necessary to control C. botulinum growth and toxin formation\n\nb. At the storage critical control point for your Pasteurized Crabmeat HACCP, the listed critical limit of “Storage cooler temperature should not exceed (b)(4) for over (b)(4). However, many of the cooler temperatures exceeded this critical limit in June and July 2023. Most notably, the temperature range was (b)(4) from July 2-8, 2023. In addition, your critical limit should ensure the products are (b)(4).\n\nFurthermore, our investigator reviewed your continuous monitoring system (CMS) records for your seafood storage cooler. The CMS data records from May 20 to July 10, 2023, revealed your seafood storage cooler temperatures ranged from (b)(4) for entire days. Additionally, employees used infrared thermometer (IR) guns to monitor the same storage cooler temperatures and for the same time span, the IR temperature recordings were logged at (b)(4).\n\nc. The receiving CCP for your Combined Molluscan Shellfish HACCP plan that includes your reduced oxygen packaged shucked raw, scallops in cans, lists a critical limit that fails to ensure the products were held at adequate temperatures continuously during transit to your facility (b)(4).\n\nd. The receiving CCP for your Scombroid fish HACCP plan, lists a critical limit that is not adequate to control histamine formation. The critical limit indicates you may receive scombroid fish with gel packs. If so, FDA recommends internal temperatures of a representative number of fish be taken at receiving. Your written response indicated that you are revising your HACCP plans to reflect the correct CCP, and seafood staff have been trained on new procedures. We find your response inadequate in that you did not provide evidence\u002Fdocumentation to demonstrate your corrective actions or that employee training was performed.\n\n2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b), (c)(4). However, your firm did not follow monitoring and verification procedures for your Combined Molluscan Shellfish, Scombroid Fish and Pasteurized Crabmeat HACCP plans. Specifically,\n\na. The monitoring procedure at the storage critical control point (CCP) for your Scombroid fish lists checking the adequacy of ice “(b)(4)”. However, your firm operates (b)(4). According to your Daily Seafood Sanitation Reports on June 3, 6, 13, 17, 18, 20, 24, and 25, 2023 and July 4, 8, and 9, 2023, the adequacy of ice was (b)(4). On June 11 and July 1-3, 2023, the adequacy of ice was not checked at all. Furthermore, the monitoring procedures don’t include taking the internal temperatures of fish to ensure the critical limit is met. The monitoring procedures don’t require a representative number of containers to be examined and the approximate number of containers in the cooler.\n\nYour written response indicated that your HACCP plans are under review and will be revised. Additionally, your response indicated that employees were trained on proper monitoring procedures; however, a new HACCP plan hasn’t been implemented yet, nor was evidence provided to document employee training was performed. This response is inadequate in that corrective actions have not been taken or implemented. You also failed to offer a timeframe on when these revisions would be completed.\n\n3. You must take appropriate corrective actions when a deviation from a critical limit occurs, to comply with 21 CFR 123.7(a). However, your corrective actions were not appropriate to control your hazards of pathogenic bacteria growth, toxin formation and C. botulinum toxin formation when your cooler temperatures for the storage of Pasteurized Crabmeat and your shucked shellfish meat deviated from your listed critical limits of “Storage cooler temperature should not exceed (b)(4) for over (b)(4)” and “Storge cooler temperature not to exceed (b)(4)”, respectively.\n\nFurthermore, your trained Seafood HACCP employee reviewed your CMS records that revealed critical limit deviations and failed to evaluate the product or conduct any type of corrective actions.\n\nYour written response indicated that employees were trained on the importance of performing necessary corrective actions; however, you failed to provide evidence that employee training was performed.\n\n4. Your HACCP plans include corrective action plans that are not in accordance with 21 CFR 123.7(b) to ensure affected product is not entered into commerce and the cause of the deviation was corrected as required by 21 CFR 123.6(c)(5). Specifically,\n\na. The CCP of cooler storage of fresh shucked shellfish meat for you Combined Molluscan Shellfish and Pasteurized Crabmeat HACCP plans are inadequate to control Clostridium botulinum growth and toxin formation. Your HACCP plans do not list corrective actions on evaluating the cumulative time and the ambient cooler temperature exposures of the affected product, rejecting the lot or diverting to a non-food use.\n\nb. The CCP’s of receiving and Finished Product Storage in the Scombroid Fish HACCP plan are inadequate to control histamine formation. Taking the internal product temperature alone at receiving does not control the hazard. Additionally, waiting until the finished product storage cooler temperature is above (b)(4) for more than (b)(4), checking the adequacy of ice and product temperature does not control the hazard. Furthermore, the HACCP plan doesn’t document chilling, holding, rejecting or diverting the lot to non-food use.\n\nYour written response indicated that your HACCP plans are under review. This response is inadequate in that corrective actions have not been taken or implemented. Additionally, you failed to offer a timeframe on when these revisions would be completed.\n\n5. You must monitor sanitation conditions and practices during processing with sufficient frequency to ensure compliance with current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs) to comply with 21 CFR 123.11 (b). However, your firm did not monitor for the adequacy of key areas of sanitation (b)(4) on June 3, 9, 13, 17, 18, 20, 24, 25 and July 4, 8 and 9, 2023. Additionally, you failed to check the adequacy of any key areas of sanitation at all on June 11 and July 1-3, 2023.\n\nYour written response indicated that employees were trained to check and record sanitation conditions and practices (b)(4) per shift; however, you failed to provide evidence that employee training was performed or adequately completed “Daily Seafood CCP and Sanitation Report” forms.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so.\n\nIf you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Please send your reply to the Food and Drug Administration, Attention: Allison Hunter, Compliance Officer, 550 Main Street, Suite 4-930, Cincinnati, Ohio 45202. If you prefer to send your response electronically, please email it to ORAHAFEAST5FirmResponses@fda.hhs.gov. If you have any questions regarding this letter, please contact Allison C. Hunter, Compliance Officer, at Allison.hunter@fda.hhs.gov or (513) 322-0629.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Euro USA Inc","euro-usa-inc-666173-11222023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feuro-usa-inc-666173-11222023","2026-10-26T08:08:36.767386+00:00","Closed Out","2024-04-16","666173","2024-09-23","Division of Human and Animal Food Operations East V","Mr. Joseph O’Donnell","2026-08-20T00:10:33.528+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","2023-11-22",{"id":96,"raw":97,"subject":12,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":105,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":110,"body_fetched_at":111,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},2406,[98,99,100,11,12,13,13,13],"\u003Ctime datetime=\"2022-10-11T13:20:00Z\">10\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-26T04:00:00Z\">09\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvero-usa-corporation-639180-09262022\">Vero USA Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ahmed Abdelhafez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vero USA Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>90 Dayton Ave Ste 14\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Passaic\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07055\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 26, 2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 639180\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ahmed Abdelhafez:\u003C\u002Fp>\n\n\u003Cp>On May 25, 2022, June 8, 2022, and July 7, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Vero USA Corporation located at 90 Dayton Ave Ste 14, Passaic, NJ 07055. We also conducted an inspection on May 14, 2021 through May 25, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations, and an amended Form FDA 483a FSVP Observations was issued to you on July 7, 2022, correcting one of the products listed.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of the emails that you sent us on June 29, 2022, and July 7, 2022 in which you indicated that your firm hired a third party to respond to the observations, and requested a one month extension. On July 13, 2022, we granted an extension and requested a response by July 29, 2022. In our July 13, 2022 email, we also explained that your response should include documentation that demonstrates your progress in complying with the FSVP requirements and your expected time frames to complete your FSVPs for the products that you import. However, since our July 13, 2022 response to your July 7, 2022 response, we have not received your additional response to the Form FDA 483a issued on July 7, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, including the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Paprika Chips from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Snacks (Corn Puffs) from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Pasteurized White Cheese- Feta from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVPs, records to demonstrate implementation of your FSVPs), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: David Trent-Carlson, Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLRESPONSES@fda.hhs.gov. Please also cc (carbon copy) David.Trent-Carlson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Trent-Carlson via email at David.Trent-Carlson@fda.hhs.gov. Please reference CMS # 639180 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTheresa Smedley\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Ahmed Abdelhafez\n\nRecipient Title\n\nOwner\n\nVero USA Corporation\n\n90 Dayton Ave Ste 14\n\nPassaic, NJ 07055\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\nSeptember 26, 2022\n\nRe: CMS # 639180\n\nDear Mr. Ahmed Abdelhafez:\n\nOn May 25, 2022, June 8, 2022, and July 7, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Vero USA Corporation located at 90 Dayton Ave Ste 14, Passaic, NJ 07055. We also conducted an inspection on May 14, 2021 through May 25, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations, and an amended Form FDA 483a FSVP Observations was issued to you on July 7, 2022, correcting one of the products listed.\n\nWe acknowledge receipt of the emails that you sent us on June 29, 2022, and July 7, 2022 in which you indicated that your firm hired a third party to respond to the observations, and requested a one month extension. On July 13, 2022, we granted an extension and requested a response by July 29, 2022. In our July 13, 2022 email, we also explained that your response should include documentation that demonstrates your progress in complying with the FSVP requirements and your expected time frames to complete your FSVPs for the products that you import. However, since our July 13, 2022 response to your July 7, 2022 response, we have not received your additional response to the Form FDA 483a issued on July 7, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any foods that you import, including the following foods:\n\n(b)(4) Paprika Chips from (b)(4), located in (b)(4)\n\nSnacks (Corn Puffs) from (b)(4), located in (b)(4)\n\nPasteurized White Cheese- Feta from (b)(4), located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVPs, records to demonstrate implementation of your FSVPs), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: David Trent-Carlson, Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLRESPONSES@fda.hhs.gov. Please also cc (carbon copy) David.Trent-Carlson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Trent-Carlson via email at David.Trent-Carlson@fda.hhs.gov. Please reference CMS # 639180 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTheresa Smedley\n\nActing Program Division Director\n\nDivision of Northeast Imports","Vero USA Corporation","vero-usa-corporation-639180-09262022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvero-usa-corporation-639180-09262022","2026-10-26T08:10:27.282069+00:00","2022-10-11","639180","Mr. Ahmed Abdelhafez","2026-08-20T01:31:14.367+00:00","2022-09-26",{"id":114,"raw":115,"subject":12,"body_html":120,"body_text":121,"firm_name":122,"letter_id":123,"created_at":124,"fei_number":19,"letter_url":125,"updated_at":126,"action_type":22,"case_status":23,"posted_date":127,"marcs_cms_no":128,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":129,"body_fetched_at":130,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},2663,[116,117,118,37,119,13,13,13],"\u003Ctime datetime=\"2022-05-17T13:20:00Z\">05\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-28T04:00:00Z\">03\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecs-usa-inc-623164-03282022\">LECS USA Inc.\u003C\u002Fa>","Foreign Supplier Verification Program (FSVP)\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Akiko Fujimoto\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LECS USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1410 Boyd St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90033\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 28, 2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 623164\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Fujimoto,\u003C\u002Fp>\n\n\u003Cp>On November 10, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of LECS USA, Inc. located at 1410 Boyd St. Los Angeles, CA 90033. We also conducted an inspection on June 19, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on November 10, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated November 29, 2021, which stated that “LECS USA INC annual sale is under one million dollars and counted as a very small importer.” During the most recent inspection, you also stated that your firm is a very small importer and that you would request a letter of guarantee from your foreign suppliers and provide a written statement that you are following the very small importer requirements. We are unable to evaluate the adequacy of your response because you did not provide documentation that your firm meets the definition of a very small importer (see 21 CFR 1.500 for the definition of a very small importer). You may choose to document your eligibility with tax forms or other accounting documents. You may find information on documenting your eligibility as a very small importer and the other requirements under 21 CFR 1.512 in the “Draft Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals” at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if you meet the definition of a very small importer, you are still required to follow FSVP requirements, including the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510 (see 21 CFR 1.512(b)(2)). If you choose to comply with the requirements for very small importers, you must document that you meet the definition of a very small importer in 21 CFR 1.500 before initially importing food as a very small importer and thereafter on an annual basis by December 31 of each calendar year (21 CFR 1.512(b)(1)(i)(A)). In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (see 21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Green Tea imported from your foreign suppliers, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Courtney Warren, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, you may contact Courtney Warren via email at Courtney.Warren@fda.hhs.gov. Please reference CMS # 623164 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kathleen Turner, DVM\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAkiko Fujimoto\n\nRecipient Title\n\nOwner\n\nLECS USA Inc.\n\n1410 Boyd St.\n\nLos Angeles, CA 90033\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nMarch 28, 2022\n\nRe: CMS # 623164\n\nDear Ms. Fujimoto,\n\nOn November 10, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of LECS USA, Inc. located at 1410 Boyd St. Los Angeles, CA 90033. We also conducted an inspection on June 19, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection on November 10, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your response dated November 29, 2021, which stated that “LECS USA INC annual sale is under one million dollars and counted as a very small importer.” During the most recent inspection, you also stated that your firm is a very small importer and that you would request a letter of guarantee from your foreign suppliers and provide a written statement that you are following the very small importer requirements. We are unable to evaluate the adequacy of your response because you did not provide documentation that your firm meets the definition of a very small importer (see 21 CFR 1.500 for the definition of a very small importer). You may choose to document your eligibility with tax forms or other accounting documents. You may find information on documenting your eligibility as a very small importer and the other requirements under 21 CFR 1.512 in the “Draft Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals” at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals.\n\nFurthermore, even if you meet the definition of a very small importer, you are still required to follow FSVP requirements, including the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510 (see 21 CFR 1.512(b)(2)). If you choose to comply with the requirements for very small importers, you must document that you meet the definition of a very small importer in 21 CFR 1.500 before initially importing food as a very small importer and thereafter on an annual basis by December 31 of each calendar year (21 CFR 1.512(b)(1)(i)(A)). In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (see 21 CFR 1.512(b)(3)(i)).\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including (b)(4) Green Tea imported from your foreign suppliers, (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Courtney Warren, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502. If you have any questions regarding this letter, you may contact Courtney Warren via email at Courtney.Warren@fda.hhs.gov. Please reference CMS # 623164 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nKathleen Turner, DVM\n\nProgram Division Director\n\nDivision of West Coast Imports","LECS USA Inc.","lecs-usa-inc-623164-03282022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecs-usa-inc-623164-03282022","2026-10-26T08:09:13.264972+00:00","2022-05-17","623164","Akiko Fujimoto","2026-08-20T01:54:01.683+00:00","Via Express Delivery","2022-03-28",{"id":134,"raw":135,"subject":12,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":18,"fei_number":19,"letter_url":144,"updated_at":145,"action_type":22,"case_status":23,"posted_date":146,"marcs_cms_no":147,"product_type":26,"closeout_date":19,"issuing_office":139,"recipient_name":148,"body_fetched_at":149,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":150,"medical_device_id":19,"response_letter_date":19},3304,[136,137,138,139,12,13,13,13],"\u003Ctime datetime=\"2021-06-22T13:20:00Z\">06\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-09T04:00:00Z\">06\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftuty-usa-llc-614625-06092021\">Tuty Usa LLC\u003C\u002Fa>","Division of Southwest Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jose R. Sanchez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tuty Usa LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1625 Airport Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Conroe\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77301-3125\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 09, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 614625\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sanchez:\u003C\u002Fp>\n\n\u003Cp>From March 29 to April 14, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Tuty USA LLC located at 1625 Airport Road, Conroe, Texas. We also conducted an inspection on November 7, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the food products that you import, including but not limited to your wheat snacks and Japanese peanuts imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and Blackberry Tartlet Cookies imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not have FSVPs for these products or for any other products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial inspection on November 7, 2018 and the follow-up inspection on April 14, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge your email response, dated April 15, 2021, where you informed us that you “have started to work to implement the program and obtain the required documentation” and have hired someone who will implement this program and get the documents ready. You did not provide any additional details, supporting documentation, or a timeframe for implementing your FSVP program.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the food products you import, including but not limited to your wheat snacks and Japanese peanuts imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Blackberry Tartlet Cookies imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>On April 2, 2021, you emailed our investigator certificates of analysis for “Japanese Style Peanut” and “Snacks Tuty,” a food defense plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not provide an explanation of these documents, describe how they would apply to your FSVP program, state that they constitute your FSVP program, or provide a record of your review of these documents. These documents alone do not constitute an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA has determined that \u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>.&nbsp; In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 216 West Village Blvd, Suite 107, Laredo, Texas 78041. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614625 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJose R. Sanchez\n\nRecipient Title\n\nOwner\n\nTuty Usa LLC\n\n1625 Airport Road\n\nConroe, TX 77301-3125\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nJune 09, 2021\n\nWARNING LETTER\n\nRe: CMS # 614625\n\nDear Mr. Sanchez:\n\nFrom March 29 to April 14, 2021, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Tuty USA LLC located at 1625 Airport Road, Conroe, Texas. We also conducted an inspection on November 7, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the food products that you import, including but not limited to your wheat snacks and Japanese peanuts imported from your foreign supplier (b)(4) and Blackberry Tartlet Cookies imported from your foreign supplier (b)(4). You did not have FSVPs for these products or for any other products you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial inspection on November 7, 2018 and the follow-up inspection on April 14, 2021, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge your email response, dated April 15, 2021, where you informed us that you “have started to work to implement the program and obtain the required documentation” and have hired someone who will implement this program and get the documents ready. You did not provide any additional details, supporting documentation, or a timeframe for implementing your FSVP program.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the food products you import, including but not limited to your wheat snacks and Japanese peanuts imported from (b)(4) and Blackberry Tartlet Cookies imported from (b)(4).\n\nOn April 2, 2021, you emailed our investigator certificates of analysis for “Japanese Style Peanut” and “Snacks Tuty,” a food defense plan for (b)(4) and a (b)(4) for (b)(4). You did not provide an explanation of these documents, describe how they would apply to your FSVP program, state that they constitute your FSVP program, or provide a record of your review of these documents. These documents alone do not constitute an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nIn addition, FDA has determined that (b)(3)(A).\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import for which you appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Melissa G. Gonzalez, Compliance Officer, the Division of Southwest Imports, 216 West Village Blvd, Suite 107, Laredo, Texas 78041. If you have any questions regarding this letter, you may contact Melissa G. Gonzalez via email at melissag.gonzalez@fda.hhs.gov. Please reference CMS # 614625 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports","Tuty Usa LLC","tuty-usa-llc-614625-06092021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftuty-usa-llc-614625-06092021","2026-10-26T08:10:16.103408+00:00","2021-06-22","614625","Jose R. Sanchez","2026-08-20T03:04:08.351+00:00","2021-06-09",{"id":152,"raw":153,"subject":157,"body_html":158,"body_text":159,"firm_name":160,"letter_id":161,"created_at":162,"fei_number":19,"letter_url":163,"updated_at":164,"action_type":22,"case_status":23,"posted_date":165,"marcs_cms_no":166,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":167,"body_fetched_at":168,"delivery_method":169,"recipient_title":19,"reference_number":170,"action_taken_date":171,"medical_device_id":19,"response_letter_date":19},21924,[154,155,156,56,157,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-28T04:00:00Z\">09\u002F28\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsnugz-usa-inc-735284-09282026\">SnugZ USA, Inc. \u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-131\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Brandon K. Mackay\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SnugZ USA, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9258 South Prosperity Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Jordan\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84081-6161\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bmackay@snugzusa.com\"> bmackay@snugzusa.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 28, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-26-131\u003C\u002Fp>\u003Cp>To Mr. Brandon K. Mackay:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, SnugZ USA, Inc., FDA Establishment Identifier (FEI) 3009188709, at 9258 South Prosperity Road, West Jordan, from April 27 to May 1, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your May 22, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, primarily distributed by your customers as promotional items. Your firm routinely failed to investigate out-of-specification (OOS) chemical and microbiological results for drug products and for \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring samples. Your firm retested failing samples or prepared and tested new samples without justification until your analysts obtained passing results. Your firm used these results to release drug product to the market without appropriate investigations into the original failing results.\u003C\u002Fp>\u003Cp>Additionally, your firm failed to conduct adequate complaint investigations. Your investigations consisted largely of email correspondence and lacked proper root cause determination and implementation of corrective actions and preventive actions (CAPA). Inadequate investigations are a repeat observation identified at your firm.\u003C\u002Fp>\u003Cp>In your response, you commit to a retrospective review of the OOS results and implemented an interim “full stop” for any initial OOS result. You also state you will review prior OOS results and customer complaints to determine product impact and ensure release decisions were scientifically justified. Your response is inadequate. You failed to provide plans on how you will ensure that OOS results and complaints are always appropriately handled. You also failed to provide adequate details of your remediations to ensure they are sustainable to prevent repeat violations.\u003C\u002Fp>\u003Cp>Passing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant chemical and microbial test results that may impact drug product quality. For more information about handling out-of-specification and failing test results and documenting your investigations, see FDA’s guidance document \u003Cem>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS result:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>\u003Cp>A comprehensive, independent review of your overall complaint system, including a retrospective review of all complaints for the last three years from the initial date of inspection with an assessment that includes, but is not limited to:\u003Cbr>o Nature of complaint, and potential associated risk\u003Cbr>o Date of first notification and subsequent contacts with complainant\u003Cbr>o Timing and sufficiency of follow-ups with the complainant to obtain photographs and the complaint sample, as well as to obtain any additional contextual information. Determination of whether relevant complaint samples were available and extent of efforts to obtain the complaint sample. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\u003Cbr>o Review of long-term history for similar or same defects.\u003Cbr>o Identification of potential causes of the defect that led to the complaint, including evaluation of whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. In the event a complaint was attributed to factors outside of the firm’s control(e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\u003C\u002Fp>\u003Cp>o CAPA steps taken including, but not limited to, manufacturing\u002Fquality improvements (e.g., manufacturing operation, raw materials, supplier, quality control), as well as recalls or heightened quality surveillance (additional testing\u002Fexaminations, adding batch to stability program).\u003Cbr>o For all complaint investigations found by the retrospective review to be deficient due to insufficient root cause or CAPA, perform a thorough analysis of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, OOS result history, batch failure history).\u003Cbr>o Based upon this independent review, provide a comprehensive assessment of the complaint system that identifies all deficiencies and needed improvements.\u003C\u002Fp>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your test method procedures allowed multiple retesting of samples following an OOS result, often until an acceptable result is obtained. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> standard operating procedure (SOP) described repreparing OOS samples and retesting multiple times without requiring investigations. The SOP requires notifying quality control management only after \u003Cstrong>(b)(4)\u003C\u002Fstrong> OOS results. Your procedure also stated that if an unidentified peak is observed during chromatographic analysis, it is at the discretion of the analyst to consult the Quality Control manager to determine whether further action is needed.\u003C\u002Fp>\u003Cp>Additionally, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Microbial Testing SOP allows retesting following an initial failure. Also, your SOP says that if the retest fails, your analysts are to use the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a second microbiological testing instrument. You routinely invalidated failing batch release results from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system and used the passing \u003Cstrong>(b)(4)\u003C\u002Fstrong> results to release product to the market without scientific justification. You could not provide any data to support this tiered testing approach or the validation of one method as superior to the other.\u003C\u002Fp>\u003Cp>In your response, you commit to implementing an interim requirement to open an OOS investigation for all initial failing results. You also commit to revising your OOS procedure to define when repeat testing, re-injection, re-vialing, etc. are allowed, when Quality Assurance authorization is required, and to require scientific justification and documentation of all data generated. Your response is inadequate because it fails to recognize the scope of your poor analytical practices. You did not address revisions to specific analytical methods, training, or systemic remediation of your routine practice of invalidating OOS results and retesting. Inadequate laboratory controls have previously been observed at your firm, and your earlier commitments to correct them and prevent their recurrence were not effective.\u003C\u002Fp>\u003Cp>These are unscientific practices and objectionable under CGMP.\u003C\u002Fp>\u003Cp>Chemical and microbial release testing, an essential quality control step, is integral in preventing distribution of unsafe products. Integrity of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with drug testing. Furthermore, the lack of reliable data compromises the Quality Unit’s (QU) ability to exercise its function of ensuring compliance with applicable standards.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\u003Cbr>o Quality unit oversight of laboratory investigations\u003Cbr>o Identification of adverse laboratory control trends\u003Cbr>o Resolution of causes of laboratory variation\u003Cbr>o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\u003Cbr>o Adequate scoping of each investigation and its CAPA\u003Cbr>o Revised OOS investigation procedures with these and other remediations\u003Cbr>o A similar review and remediation of your system for handling out-of-limit findings (i.e., data that falls outside action limits)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate identity testing of incoming components used in the manufacture of your OTC drug products. You also failed to collect representative samples from each lot of components. In some cases, you relied on identity test results from previously tested component lots when receiving new shipments of the same component lot. Additionally, you failed to establish the reliability of your suppliers’ certificates of analyses (COAs) at appropriate intervals and accepted COAs without confirmatory testing.\u003C\u002Fp>\u003Cp>In your response, you commit to revising your supplier qualification and raw material sampling SOPs. You commit to reducing testing criteria and identifying an outside laboratory to perform confirmatory testing for your suppliers’ COAs. You also commit to testing each shipment of components received prior to use. Your response is inadequate. You did not provide sufficient details about your planned procedural improvements, the testing to be performed, your strategy for reduced testing, nor did you commit to evaluating component retains.\u003C\u002Fp>\u003Cp>Without adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system including, but not limited to:\u003Cbr>o Evaluating all suppliers of materials (components, containers, and closures) to determine whether they are reliable and appropriately qualified\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o A review to ensure assigned expiration or retest dates are appropriate and supported by data\u003Cbr>o Adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your QU failed to establish and exercise its authority to adequately oversee the manufacturing, testing, packing, holding, review, and release of your OTC drug products. Your firm’s inadequate quality oversight resulted in significant deficiencies in analytical and production record review, investigations, and quality system controls to ensure compliance with CGMP requirements. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adequate procedures ensuring appropriate document controls of production and test records. (21 CFR 211.22(d)).\u003C\u002Fli>\u003Cli>Adequate validation of cleaning procedures (21 CFR 211.67(b)).\u003C\u002Fli>\u003Cli>Performance of periodic (i.e. at least annual) product quality reviews (21 CFR 211.180(e)).\u003C\u002Fli>\u003Cli>Adequate documentation of each significant step in batch production records (21 CFR 211.188(b)).\u003C\u002Fli>\u003Cli>Adequate review of all production and test records, including deviations, OOS results, and audit trails, prior to releasing drug product to the market (21 CFR 211.192).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In a previous April 1, 2022 Regulatory Meeting, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3009188709 and ATTN: Compliance Officer Christina Capacci-Daniel in the letter.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Return Receipt Requested\n\nReference #:\n\n320-26-131\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Brandon K. Mackay\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nSnugZ USA, Inc.\n\n9258 South Prosperity Road\n\nWest Jordan, UT 84081-6161\n\nUnited States\n\nbmackay@snugzusa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSeptember 28, 2026\nWARNING LETTER\nReference number: 320-26-131\nTo Mr. Brandon K. Mackay:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your products and facilities. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, SnugZ USA, Inc., FDA Establishment Identifier (FEI) 3009188709, at 9258 South Prosperity Road, West Jordan, from April 27 to May 1, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your May 22, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm manufactures over-the-counter (OTC) drug products such as (b)(4) and (b)(4), primarily distributed by your customers as promotional items. Your firm routinely failed to investigate out-of-specification (OOS) chemical and microbiological results for drug products and for (b)(4) system monitoring samples. Your firm retested failing samples or prepared and tested new samples without justification until your analysts obtained passing results. Your firm used these results to release drug product to the market without appropriate investigations into the original failing results.\nAdditionally, your firm failed to conduct adequate complaint investigations. Your investigations consisted largely of email correspondence and lacked proper root cause determination and implementation of corrective actions and preventive actions (CAPA). Inadequate investigations are a repeat observation identified at your firm.\nIn your response, you commit to a retrospective review of the OOS results and implemented an interim “full stop” for any initial OOS result. You also state you will review prior OOS results and customer complaints to determine product impact and ensure release decisions were scientifically justified. Your response is inadequate. You failed to provide plans on how you will ensure that OOS results and complaints are always appropriately handled. You also failed to provide adequate details of your remediations to ensure they are sustainable to prevent repeat violations.\nPassing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate aberrant chemical and microbial test results that may impact drug product quality. For more information about handling out-of-specification and failing test results and documenting your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F158416\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS result:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit decision authority, and is fully supported by executive management.\nA comprehensive, independent review of your overall complaint system, including a retrospective review of all complaints for the last three years from the initial date of inspection with an assessment that includes, but is not limited to:\no Nature of complaint, and potential associated risk\no Date of first notification and subsequent contacts with complainant\no Timing and sufficiency of follow-ups with the complainant to obtain photographs and the complaint sample, as well as to obtain any additional contextual information. Determination of whether relevant complaint samples were available and extent of efforts to obtain the complaint sample. If insufficient attempts were made, identify the root cause(s) for not adequately pursuing their return.\no Review of long-term history for similar or same defects.\no Identification of potential causes of the defect that led to the complaint, including evaluation of whether the scientific justification and evidence relating to the identified root cause(s) were adequately documented. In the event a complaint was attributed to factors outside of the firm’s control(e.g., user error), assess the strength of this determination and whether it was based on conclusive or inconclusive information.\no CAPA steps taken including, but not limited to, manufacturing\u002Fquality improvements (e.g., manufacturing operation, raw materials, supplier, quality control), as well as recalls or heightened quality surveillance (additional testing\u002Fexaminations, adding batch to stability program).\no For all complaint investigations found by the retrospective review to be deficient due to insufficient root cause or CAPA, perform a thorough analysis of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, OOS result history, batch failure history).\no Based upon this independent review, provide a comprehensive assessment of the complaint system that identifies all deficiencies and needed improvements.\n\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour test method procedures allowed multiple retesting of samples following an OOS result, often until an acceptable result is obtained. For example, your (b)(4) standard operating procedure (SOP) described repreparing OOS samples and retesting multiple times without requiring investigations. The SOP requires notifying quality control management only after (b)(4) OOS results. Your procedure also stated that if an unidentified peak is observed during chromatographic analysis, it is at the discretion of the analyst to consult the Quality Control manager to determine whether further action is needed.\nAdditionally, your (b)(4) Microbial Testing SOP allows retesting following an initial failure. Also, your SOP says that if the retest fails, your analysts are to use the (b)(4), a second microbiological testing instrument. You routinely invalidated failing batch release results from the (b)(4) system and used the passing (b)(4) results to release product to the market without scientific justification. You could not provide any data to support this tiered testing approach or the validation of one method as superior to the other.\nIn your response, you commit to implementing an interim requirement to open an OOS investigation for all initial failing results. You also commit to revising your OOS procedure to define when repeat testing, re-injection, re-vialing, etc. are allowed, when Quality Assurance authorization is required, and to require scientific justification and documentation of all data generated. Your response is inadequate because it fails to recognize the scope of your poor analytical practices. You did not address revisions to specific analytical methods, training, or systemic remediation of your routine practice of invalidating OOS results and retesting. Inadequate laboratory controls have previously been observed at your firm, and your earlier commitments to correct them and prevent their recurrence were not effective.\nThese are unscientific practices and objectionable under CGMP.\nChemical and microbial release testing, an essential quality control step, is integral in preventing distribution of unsafe products. Integrity of data is fundamentally compromised when there is a failure to record or maintain complete and accurate records of test results or conditions associated with drug testing. Furthermore, the lack of reliable data compromises the Quality Unit’s (QU) ability to exercise its function of ensuring compliance with applicable standards.\nIn response to this letter, provide:\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include but not be limited to addressing the following:\no Quality unit oversight of laboratory investigations\no Identification of adverse laboratory control trends\no Resolution of causes of laboratory variation\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified\no Adequate scoping of each investigation and its CAPA\no Revised OOS investigation procedures with these and other remediations\no A similar review and remediation of your system for handling out-of-limit findings (i.e., data that falls outside action limits)\n3. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate identity testing of incoming components used in the manufacture of your OTC drug products. You also failed to collect representative samples from each lot of components. In some cases, you relied on identity test results from previously tested component lots when receiving new shipments of the same component lot. Additionally, you failed to establish the reliability of your suppliers’ certificates of analyses (COAs) at appropriate intervals and accepted COAs without confirmatory testing.\nIn your response, you commit to revising your supplier qualification and raw material sampling SOPs. You commit to reducing testing criteria and identifying an outside laboratory to perform confirmatory testing for your suppliers’ COAs. You also commit to testing each shipment of components received prior to use. Your response is inadequate. You did not provide sufficient details about your planned procedural improvements, the testing to be performed, your strategy for reduced testing, nor did you commit to evaluating component retains.\nWithout adequate testing and verification of supplier results, you do not have scientific evidence that your incoming components conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system including, but not limited to:\no Evaluating all suppliers of materials (components, containers, and closures) to determine whether they are reliable and appropriately qualified\no An assessment of all materials to determine whether they are consistently of acceptable quality\no A review to ensure assigned expiration or retest dates are appropriate and supported by data\no Adequacy of the supplier qualification program and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n4. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour QU failed to establish and exercise its authority to adequately oversee the manufacturing, testing, packing, holding, review, and release of your OTC drug products. Your firm’s inadequate quality oversight resulted in significant deficiencies in analytical and production record review, investigations, and quality system controls to ensure compliance with CGMP requirements. For example, your QU failed to ensure:\nAdequate procedures ensuring appropriate document controls of production and test records. (21 CFR 211.22(d)).\nAdequate validation of cleaning procedures (21 CFR 211.67(b)).\nPerformance of periodic (i.e. at least annual) product quality reviews (21 CFR 211.180(e)).\nAdequate documentation of each significant step in batch production records (21 CFR 211.188(b)).\nAdequate review of all production and test records, including deviations, OOS results, and audit trails, prior to releasing drug product to the market (21 CFR 211.192).\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found your QU is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nRepeat Violations at Facility\nIn a previous April 1, 2022 Regulatory Meeting, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nUnresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3009188709 and ATTN: Compliance Officer Christina Capacci-Daniel in the letter.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","SnugZ USA, Inc.","snugz-usa-inc-735284-09282026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsnugz-usa-inc-735284-09282026","2026-11-17T01:02:03.701861+00:00","2026-10-20","735284","Mr. Brandon K. Mackay","2026-10-27T01:19:28.513+00:00","Via Electronic Mail - Return Receipt Requested","320-26-131","2026-09-28",{"id":173,"raw":174,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":189,"closeout_date":19,"issuing_office":178,"recipient_name":190,"body_fetched_at":191,"delivery_method":192,"recipient_title":19,"reference_number":19,"action_taken_date":193,"medical_device_id":19,"response_letter_date":19},348,[175,176,177,178,179,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-10T04:00:00Z\">09\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025\">Eniva USA, Inc.\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andrew J Baechler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eniva USA, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2700 Campus Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Plymouth\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55441-2601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:andyb@eniva.com\"> andyb@eniva.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 10, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #706565\u003C\u002Fp>\u003Cp>Dear Mr. Baechler:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents. However, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\u003C\u002Fp>\u003Cul>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003Cli>Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\u003C\u002Fp>\u003Cp>2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\u003C\u002Fp>\u003Cp>We have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>In addition to the above-mentioned violations, we also have the following comment:\u003C\u002Fp>\u003Cp>We conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\u003C\u002Fp>\u003Cul>\u003Cli>Is management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\u003C\u002Fli>\u003Cli>Has management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\u003C\u002Fli>\u003Cli>Has management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\u003C\u002Fli>\u003Cli>Please provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAndrew J Baechler\n\nRecipient Title\n\nCEO\n\nEniva USA, Inc.\n\n2700 Campus Dr.\n\nPlymouth, MN 55441-2601\n\nUnited States\n\nandyb@eniva.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nSeptember 10, 2025\nWARNING LETTER\nCMS #706565\nDear Mr. Baechler:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 2700 Campus Dr., Plymouth, MN, from November 19, 2024, through January 13, 2025. Based on inspectional findings and review of product labels collected during the inspections, as well as review of your website, www.eniva.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on January 13, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response on February 5, 2025, and we address your response below.\nAdulterated Dietary Supplements\nThe inspection of your facility from November 19, 2024, through January 13, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your Immune Support (previously called Cold Buster) and Ashwagandha Gummies dietary supplements to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1) You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplements, as required by 21 CFR 111.70(e). During the inspection, your Senior Quality Manager stated that your finished product specifications are maintained in the form of blank “(b)(4)” documents. However, your “(b)(4)” documents do not establish product specifications that confirm the identity, purity, strength, and composition of the finished batches of your Cold Buster (now Immune Support) and Ashwagandha Gummies dietary supplements. Specifically:\nYour “(b)(4)” document for your Cold Buster (now Immune Support) lists appearance, color, odor, conductivity, pH, percent solids, and specific gravity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Cold Buster product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nYour “(b)(4)” document for your Ashwaghanda Gummies lists appearance, color, odor, and water activity as “(b)(4).” These factors do not constitute unique criteria that can confirm the identity of the Ashwaghanda Gummies product. Additionally, these factors do not—either alone or in conjunction—evaluate the purity, strength, and composition of this finished product.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you plan to update finished product specification forms for the finished dietary supplement products you manufacture, including Immune Support and Ashwagandha Gummies. However, to date, you have not submitted any evidence of further corrective action.\n2) You failed to make and keep documentation of any material review and disposition decision and follow-up, as required by 21 CFR 111.140(b)(3). Specifically, your Senior Quality Manager stated that when “(b)(4)” results had been encountered by your firm since your last inspection for incoming components and outgoing dietary supplements, you failed to document the investigation, findings, material review by quality, and the disposition of affected materials.\nWe have reviewed your response to the FDA Form 483, received February 5, 2025, and find it does not adequately address the violation. In your response, you stated that you will review and update your SOP QS-009, “(b)(4),” and proceed to document all investigations. However, to date, you have not submitted any evidence of corrective action.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nIn addition to the above-mentioned violations, we also have the following comment:\nWe conducted a case assessment and review of your firm’s response regarding observation 1, namely 21 CFR 114.83 for acid foods. Your response to this observation appears inadequate. We request the following be addressed by your firm:\nIs management able to furnish the supporting documents from the University of Minnesota which support the conclusion that these products are acid foods?\nHas management made formulation changes to the following original four products: Vibe Original, Vibe 2.0, Vibe Apple and Vibe Kids?\nHas management fully evaluated the other products, not listed above, to determine if they are acidified or acid food products?\nPlease provide a list of ingredients, pH for all ingredients, formulation, and finished product pH for the Vibe product for review. Does your firm add acid ingredients to shift the product pH? What is the pH of the product before acidulent is added?\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #706565 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Eniva USA, Inc.","eniva-usa-inc-706565-09102025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feniva-usa-inc-706565-09102025","2026-10-26T08:08:35.579466+00:00","2026-02-03","706565","Dietary Supplements","Andrew J Baechler","2026-08-19T05:07:51.096+00:00","Via Email","2025-09-10",{"id":195,"raw":196,"subject":202,"body_html":203,"body_text":204,"firm_name":205,"letter_id":206,"created_at":184,"fei_number":19,"letter_url":207,"updated_at":208,"action_type":22,"case_status":23,"posted_date":209,"marcs_cms_no":210,"product_type":211,"closeout_date":19,"issuing_office":200,"recipient_name":212,"body_fetched_at":213,"delivery_method":214,"recipient_title":19,"reference_number":19,"action_taken_date":215,"medical_device_id":19,"response_letter_date":19},170,[197,198,199,200,201,13,13,13],"\u003Ctime datetime=\"2026-05-12T04:00:00Z\">05\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-03T04:00:00Z\">04\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fridley-usa-inc-720800-04032026\">Ridley USA Inc. \u003C\u002Fa>","Center for Veterinary Medicine","CGMP\u002FMedicated Feeds\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FMedicated Feeds\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL NO HARD COPY TO FOLLOW\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Darrell K. Meyer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Plant Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ridley USA Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2420 Old Highway 218 South\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Iowa City\u003C\u002Fspan>, \u003Cspan>IA\u003C\u002Fspan> \u003Cspan>52246-5818\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:darrell.meyer@alltech.com\"> darrell.meyer@alltech.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 720800\u003C\u002Fp>\u003Cp>April 3, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Meyer,\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your licensed medicated feed manufacturing facility located at 2420 Old Highway 218 South, Iowa City, Iowa, from September 2 through September 17, 2025. The inspection was conducted in response to a Reportable Food Registry (RFR) report you filed on August 28, 2025, after you discovered you manufactured a medicated feed for cattle that contained an undeclared new animal drug, monensin, instead of the intended Veterinary Feed Directive (VFD) drug, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The drug mix-up resulted in at least 16 cattle deaths. In response, you initiated a voluntary Class I recall on August 26, 2025, for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We received and evaluated your written responses to the amended Form FDA 483, Inspectional Observations (FDA 483), dated October 16, and November 6, 2025. In these responses, you stated additional documentation would be provided when your corrections are complete. As of the date of this letter, you have provided limited documentation, and therefore we are unable to fully assess your voluntary corrections.\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements found in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is prohibited.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Additionally, the investigator found evidence of significant violations of FDA’s Current Good Manufacturing Practice for Medicated Feeds requirements, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements causes your medicated feed to be adulterated.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The inspection revealed evidence you manufactured and distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained unintended monensin. This Type B medicated cattle feed containing a Type A medicated article of monensin is unsafe because the new animal drug it contains was not used in conformance with the drug approval.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As a result, the medicated feed is adulterated.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the food or drug being adulterated or misbranded is prohibited.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You may find the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and its implementing regulations through links on FDA’s website at www.fda.gov.\u003C\u002Fp>\u003Cp>At the close of the inspection, you were issued an amended FDA 483. As stated above, we received your written responses, dated October 16, and November 6, 2025, to the amended FDA 483. We address your proposed corrective actions below in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, Subparts A, C, D, E, and F. During the inspection of your facility, the FDA investigator observed evidence of significant violations of these requirements, which included the following:\u003C\u002Fp>\u003Cp>1. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis identified “incorrect ingredient added due to operator error” at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step as a known or reasonably foreseeable hazard. In your hazard analysis you determined that a preventive control was not required due to your prerequisite programs. Your hazard analysis states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” On August 12, 2025, an employee added \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (monensin) instead of the formulated \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> while manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This lot of medicated feed was distributed and fed to cattle. On August 28, 2025, you filed an RFR report that identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> contained undeclared monensin and no \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You attributed the use of this product to cattle deaths in your RFR report. Your prerequisite programs did not reduce the probability of drug contamination occurring in the absence of a preventive control due to incorrect medicated articles being added in your medicated feeds at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>In your supplemental written response dated November 6, 2025, you provided an updated Corrective Action Report, CAR No. 902, and Animal Food Safety Plan Development and Maintenance standard operating procedure (SOP), 500-SOP-RID. The Corrective Action Record documents review of your food safety plan, in accordance with your SOP, which includes “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as justification you reduced the probability of the “incorrect ingredient added due to operator error” hazard from occurring. However, you did not present an updated hazard analysis or sufficient records to demonstrate implementation of your prerequisite programs will reduce the probability of occurrence of the hazard. Therefore, we are unable to fully evaluate your corrections at this time.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice (CGMP) for Medicated Feed Requirements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your animal food facility is subject to the medicated feed CGMP regulations for licensed medicated animal feed manufacturers found in 21 CFR 225.10-225.115. During the inspection of your facility, the FDA investigator noted evidence of significant violations of these requirements, which included the following:\u003C\u002Fp>\u003Cp>2. You failed to properly identify, handle, and control drugs in the mixing areas to maintain their integrity and identity, as required by 21 CFR 225.42(b)(4).\u003C\u002Fp>\u003Cp>Specifically, you manufactured \u003Cstrong>(b)(4)\u003C\u002Fstrong> pounds of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> that contained a Type A medicated article, monensin, instead of the VFD drug, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, required by the formula. Upon staging ingredients for the production batch, an employee staged \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (monensin) instead of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> required by the formula. A \u003Cstrong>(b)(4)\u003C\u002Fstrong> operator added the staged monensin without reviewing the drug labeling and comparing the drug labeling to your Lot Usage Records or batch production records to ensure proper formulation.\u003C\u002Fp>\u003Cp>Furthermore, on August 12, 2025, you did not document the actual use of medicated articles while manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by 21 CFR 225.42(b)(6). The \u003Cstrong>(b)(4)\u003C\u002Fstrong> operator completed the Lot Usage Records incorrectly to indicate \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was used to manufacture the medicated feed when \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was used instead. Therefore, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> inventory Lot Usage Records were not maintained adequately to include the drug used, quantity of drug used, and production batch of medicated feed in which the drug was used.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response\u003C\u002Fu>\u003Cbr>In your supplemental written response dated November 6, 2025, you provided the updated 030-SOP-RID version 2, “Drug and Critical Premix Handling,” with training records documenting review and assessment of the updated procedure. Your updated procedure permits \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also provided example Lot Usage Records - \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your response dated November 6, 2025, to demonstrate implementation of the procedure.\u003C\u002Fp>\u003Cp>Additionally, in your written response dated October 16, 2025, you explained your expanded use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> area. You also provided examples documenting the barcode systems with photographs identified as the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> (Monensin)” for a bag of \u003Cstrong>(b)(4)\u003C\u002Fstrong> with barcode, and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with barcode for an apparent bag of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>However, you did not provide supporting records in your written responses, such as corresponding batch production records and Lot Usage Records, to demonstrate if products were correctly formulated. Therefore, we are unable to fully evaluate your corrections.\u003C\u002Fp>\u003Cp>3. You did not perform a daily comparison between the actual and theoretical amounts of the drugs used, as required by 21 CFR 225.42(b)(7).\u003C\u002Fp>\u003Cp>Specifically, you did not reconcile your actual and theoretical drug use in your Lot Usage Record between August 12 and August 26, 2025. For example:\u003C\u002Fp>\u003Cul>\u003Cli>The Lot Usage Record for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, documented the drug was used in \u003Cstrong>(b)(4)\u003C\u002Fstrong> on August 12, 2025. However, based on the RFR you filed on August 28, 2025, you determined the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not added to this feed. You did not conduct a \u003Cstrong>(b)(4)\u003C\u002Fstrong> comparison of the actual amount of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used with the theoretical usage and only performed a theoretical use reconciliation at the end of the production day on August 12, 2025. An actual inventory of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not conducted until August 26, 2025, which revealed your inventory was not accurate.\u003C\u002Fli>\u003Cli>You conducted only a theoretical use reconciliation for VFD feeds containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on August 22, 2025.\u003C\u002Fli>\u003Cli>The Lot Usage Record for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, did not document that you conducted any reconciliations of this lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on August 12 and August 13, 2025, even though the drug was used in the manufacturing of medicated feed products.\u003C\u002Fli>\u003Cli>You manufactured medicated feed products containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without any reconciliations of theoretical and actual amounts between August 19 and August 21, 2025.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You use Type A medicated articles to manufacture Type B medicated feeds. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> comparison between theoretical and actual drug use requirement in 21 CFR 225.42(b)(7) assists in ensuring proper drug use. If you had been following these requirements and comparing the theoretical inventory against the actual inventory, you may have found the quantity discrepancy earlier and identified that the incorrect ingredient had been added. This would have enabled you to hold or recall the \u003Cstrong>(b)(4)\u003C\u002Fstrong> medicated feed more promptly.\u003C\u002Fp>\u003Cp>\u003Cu>Evaluation of your response:\u003C\u002Fu>\u003Cbr>In your written response dated October 16, 2025, you stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> will be performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We note your updated 030-SOP-RID, “Drug and Critical Premix Handling,” does not describe steps for corporate verification. You also provided example Lot Usage Records - one each for \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your written response dated November 6, 2025. The Lot Usage Records showed \u003Cstrong>(b)(4)\u003C\u002Fstrong> reconciliation was documented by employees. However, you provided only one occurrence of corporate review for each drug. We are unable to determine the consistent implementation of your corrections at this time.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory action, or where appropriate, legal action.\u003C\u002Fp>\u003Cp>FDA has the following comments regarding the inspection of your facility.\u003C\u002Fp>\u003Cp>1. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is regulated as a VFD drug and \u003Cstrong>(b)(4)\u003C\u002Fstrong> is intended to be a VFD feed.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As a distributor (who manufactures VFD feed), you are responsible for the judicious use of the drug and medicated feed to ensure all finished products conform to the written VFD within the veterinarian-client-patient relationship.\u003C\u002Fp>\u003Cp>2. Your hazard analysis identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> toxicity as a hazard requiring a process preventive control. You implemented 015-USFO-SOP, “Product Scheduling Requirements – Non-Medication,” which requires \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You told the FDA investigator that you intended to validate the preventive control and stated in your October 16 and November 6, 2025, written responses that process validation will be provided to FDA once it is complete. We have not received your validation study for this facility as of the date of this letter. We remind you of the requirements for validation of process preventive controls found within 21 CFR Part 507.\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Parts 507, 225, and 558, see:\u003Cbr>• For Industry | FDA (https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fresources-you\u002Findustry)\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration within fifteen (15) working days.\u003C\u002Fp>\u003Cp>The FDA, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\u003C\u002Fp>\u003Cp>Please direct your electronic correspondence to Compliance Officer Andrew Howard at Andrew.Howard@fda.hhs.gov. If you have questions regarding this letter, please contact Compliance Officer Andrew Howard by telephone at (410) 779-5125, or by the email above.\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Isaac K. Carney\u003Cbr>Director of Food Compliance, Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc:\u003Cbr>Wyatt L. Garriott, Quality Food Safety Regional Manager\u003Cbr>Ridley USA Inc.\u003Cbr>wyatt.garriott@alltech.com\u003C\u002Fp>\u003Cp>Alan Keller, Feed &amp; Fertilizer Chief\u003Cbr>Iowa Department of Agriculture &amp; Land Stewardship\u003Cbr>1305 East Walnut Street\u003Cbr>Des Moines, Iowa 50319\u003Cbr>alan.keller@iowaagriculture.gov\u003Cbr>______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 342(uu)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B] and 21 CFR 225.1(b)(1).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 512(a)(2)(A) of the FD&amp;C Act [21 U.S.C. § 360b(a)(2)(A)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See Section 501(a)(6) of the FD&amp;C Act [21 U.S.C. § 351(a)(6)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 558.6 and 21 CFR 558.128.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR Part 507.47.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL NO HARD COPY TO FOLLOW\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nDarrell K. Meyer\n\nRecipient Title\n\nPlant Manager\n\nRidley USA Inc.\n\n2420 Old Highway 218 South\n\nIowa City, IA 52246-5818\n\nUnited States\n\ndarrell.meyer@alltech.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nCMS # 720800\nApril 3, 2026\nDear Mr. Meyer,\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your licensed medicated feed manufacturing facility located at 2420 Old Highway 218 South, Iowa City, Iowa, from September 2 through September 17, 2025. The inspection was conducted in response to a Reportable Food Registry (RFR) report you filed on August 28, 2025, after you discovered you manufactured a medicated feed for cattle that contained an undeclared new animal drug, monensin, instead of the intended Veterinary Feed Directive (VFD) drug, (b)(4). The drug mix-up resulted in at least 16 cattle deaths. In response, you initiated a voluntary Class I recall on August 26, 2025, for (b)(4), lot (b)(4). We received and evaluated your written responses to the amended Form FDA 483, Inspectional Observations (FDA 483), dated October 16, and November 6, 2025. In these responses, you stated additional documentation would be provided when your corrections are complete. As of the date of this letter, you have provided limited documentation, and therefore we are unable to fully assess your voluntary corrections.\nDuring the inspection, the FDA investigator found evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals requirements found in Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which causes your products to be adulterated because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health.1 In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of 21 CFR Part 507 is prohibited.2\nAdditionally, the investigator found evidence of significant violations of FDA’s Current Good Manufacturing Practice for Medicated Feeds requirements, 21 CFR Part 225. Failure of your medicated feed mill to comply with these requirements causes your medicated feed to be adulterated.3\nThe inspection revealed evidence you manufactured and distributed (b)(4) that contained unintended monensin. This Type B medicated cattle feed containing a Type A medicated article of monensin is unsafe because the new animal drug it contains was not used in conformance with the drug approval.4 As a result, the medicated feed is adulterated.5\nThe doing of any act to a food or drug after shipment of the food or drug and\u002For its components in interstate commerce and while the food or drug is held for sale (whether or not the first sale) that results in the food or drug being adulterated or misbranded is prohibited.6\nYou may find the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations through links on FDA’s website at www.fda.gov.\nAt the close of the inspection, you were issued an amended FDA 483. As stated above, we received your written responses, dated October 16, and November 6, 2025, to the amended FDA 483. We address your proposed corrective actions below in relation to each of the noted violations.\nHazard Analysis and Risk-Based Preventive Controls Requirements\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, Subparts A, C, D, E, and F. During the inspection of your facility, the FDA investigator observed evidence of significant violations of these requirements, which included the following:\n1. You failed to sufficiently assess the probability that a hazard will occur in the absence of preventive controls, as required by 21 CFR 507.33(c)(1).\nSpecifically, your hazard analysis identified “incorrect ingredient added due to operator error” at the “(b)(4)” step as a known or reasonably foreseeable hazard. In your hazard analysis you determined that a preventive control was not required due to your prerequisite programs. Your hazard analysis states that (b)(4).” On August 12, 2025, an employee added (b)(4) bags of (b)(4) (monensin) instead of the formulated (b)(4) bags of (b)(4) while manufacturing (b)(4), lot (b)(4). This lot of medicated feed was distributed and fed to cattle. On August 28, 2025, you filed an RFR report that identified (b)(4) contained undeclared monensin and no (b)(4). You attributed the use of this product to cattle deaths in your RFR report. Your prerequisite programs did not reduce the probability of drug contamination occurring in the absence of a preventive control due to incorrect medicated articles being added in your medicated feeds at the “(b)(4)” step.\nEvaluation of your response:\nIn your supplemental written response dated November 6, 2025, you provided an updated Corrective Action Report, CAR No. 902, and Animal Food Safety Plan Development and Maintenance standard operating procedure (SOP), 500-SOP-RID. The Corrective Action Record documents review of your food safety plan, in accordance with your SOP, which includes “(b)(4)” as justification you reduced the probability of the “incorrect ingredient added due to operator error” hazard from occurring. However, you did not present an updated hazard analysis or sufficient records to demonstrate implementation of your prerequisite programs will reduce the probability of occurrence of the hazard. Therefore, we are unable to fully evaluate your corrections at this time.\nCurrent Good Manufacturing Practice (CGMP) for Medicated Feed Requirements\nYour animal food facility is subject to the medicated feed CGMP regulations for licensed medicated animal feed manufacturers found in 21 CFR 225.10-225.115. During the inspection of your facility, the FDA investigator noted evidence of significant violations of these requirements, which included the following:\n2. You failed to properly identify, handle, and control drugs in the mixing areas to maintain their integrity and identity, as required by 21 CFR 225.42(b)(4).\nSpecifically, you manufactured (b)(4) pounds of (b)(4), lot (b)(4) that contained a Type A medicated article, monensin, instead of the VFD drug, (b)(4), required by the formula. Upon staging ingredients for the production batch, an employee staged (b)(4) of (b)(4) (monensin) instead of the (b)(4) required by the formula. A (b)(4) operator added the staged monensin without reviewing the drug labeling and comparing the drug labeling to your Lot Usage Records or batch production records to ensure proper formulation.\nFurthermore, on August 12, 2025, you did not document the actual use of medicated articles while manufacturing (b)(4) of (b)(4), lot (b)(4), as required by 21 CFR 225.42(b)(6). The (b)(4) operator completed the Lot Usage Records incorrectly to indicate (b)(4), lot (b)(4), was used to manufacture the medicated feed when (b)(4), lot (b)(4), was used instead. Therefore, your (b)(4) inventory Lot Usage Records were not maintained adequately to include the drug used, quantity of drug used, and production batch of medicated feed in which the drug was used.\nEvaluation of your response\nIn your supplemental written response dated November 6, 2025, you provided the updated 030-SOP-RID version 2, “Drug and Critical Premix Handling,” with training records documenting review and assessment of the updated procedure. Your updated procedure permits (b)(4). You also provided example Lot Usage Records - (b)(4), and (b)(4) in your response dated November 6, 2025, to demonstrate implementation of the procedure.\nAdditionally, in your written response dated October 16, 2025, you explained your expanded use of (b)(4) area. You also provided examples documenting the barcode systems with photographs identified as the “(b)(4)” for manufacturing (b)(4), “(b)(4) (Monensin)” for a bag of (b)(4) with barcode, and “(b)(4)” with barcode for an apparent bag of (b)(4).\nHowever, you did not provide supporting records in your written responses, such as corresponding batch production records and Lot Usage Records, to demonstrate if products were correctly formulated. Therefore, we are unable to fully evaluate your corrections.\n3. You did not perform a daily comparison between the actual and theoretical amounts of the drugs used, as required by 21 CFR 225.42(b)(7).\nSpecifically, you did not reconcile your actual and theoretical drug use in your Lot Usage Record between August 12 and August 26, 2025. For example:\nThe Lot Usage Record for (b)(4), lot (b)(4), documented the drug was used in (b)(4) on August 12, 2025. However, based on the RFR you filed on August 28, 2025, you determined the (b)(4), lot (b)(4), was not added to this feed. You did not conduct a (b)(4) comparison of the actual amount of (b)(4), lot (b)(4), used with the theoretical usage and only performed a theoretical use reconciliation at the end of the production day on August 12, 2025. An actual inventory of (b)(4), lot (b)(4), was not conducted until August 26, 2025, which revealed your inventory was not accurate.\nYou conducted only a theoretical use reconciliation for VFD feeds containing (b)(4), lot (b)(4), on August 22, 2025.\nThe Lot Usage Record for (b)(4), lot (b)(4), did not document that you conducted any reconciliations of this lot of (b)(4) on August 12 and August 13, 2025, even though the drug was used in the manufacturing of medicated feed products.\nYou manufactured medicated feed products containing (b)(4), lot (b)(4), without any reconciliations of theoretical and actual amounts between August 19 and August 21, 2025.\nYou use Type A medicated articles to manufacture Type B medicated feeds. The (b)(4) comparison between theoretical and actual drug use requirement in 21 CFR 225.42(b)(7) assists in ensuring proper drug use. If you had been following these requirements and comparing the theoretical inventory against the actual inventory, you may have found the quantity discrepancy earlier and identified that the incorrect ingredient had been added. This would have enabled you to hold or recall the (b)(4) medicated feed more promptly.\nEvaluation of your response:\nIn your written response dated October 16, 2025, you stated that (b)(4) will be performed for (b)(4). We note your updated 030-SOP-RID, “Drug and Critical Premix Handling,” does not describe steps for corporate verification. You also provided example Lot Usage Records - one each for (b)(4)%, and (b)(4) in your written response dated November 6, 2025. The Lot Usage Records showed (b)(4) reconciliation was documented by employees. However, you provided only one occurrence of corporate review for each drug. We are unable to determine the consistent implementation of your corrections at this time.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to regulatory action, or where appropriate, legal action.\nFDA has the following comments regarding the inspection of your facility.\n1. (b)(4) is regulated as a VFD drug and (b)(4) is intended to be a VFD feed.7 As a distributor (who manufactures VFD feed), you are responsible for the judicious use of the drug and medicated feed to ensure all finished products conform to the written VFD within the veterinarian-client-patient relationship.\n2. Your hazard analysis identified (b)(4) toxicity as a hazard requiring a process preventive control. You implemented 015-USFO-SOP, “Product Scheduling Requirements – Non-Medication,” which requires (b)(4). You told the FDA investigator that you intended to validate the preventive control and stated in your October 16 and November 6, 2025, written responses that process validation will be provided to FDA once it is complete. We have not received your validation study for this facility as of the date of this letter. We remind you of the requirements for validation of process preventive controls found within 21 CFR Part 507.8\nFor more information about FDA’s current thinking on the requirements of 21 CFR Parts 507, 225, and 558, see:\n• For Industry | FDA (https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fresources-you\u002Findustry)\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration within fifteen (15) working days.\nThe FDA, Center for Veterinary Medicine, Office of Surveillance and Compliance is encouraging electronic submission of any response you choose to submit to this letter. We encourage you to submit files up to 100 megabytes in a single email, and to divide files greater than 100 megabytes so they may be submitted as smaller files in separate emails. If you submit electronic correspondence, please ensure that your facility’s name, the CMS number at the top of this letter, and the inspection location are included in your correspondence. We intend to issue an electronic acknowledgement upon receipt of your email.\nPlease direct your electronic correspondence to Compliance Officer Andrew Howard at Andrew.Howard@fda.hhs.gov. If you have questions regarding this letter, please contact Compliance Officer Andrew Howard by telephone at (410) 779-5125, or by the email above.\n\u002FS\u002F\nIsaac K. Carney\nDirector of Food Compliance, Office of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food and Drug Administration\nCc:\nWyatt L. Garriott, Quality Food Safety Regional Manager\nRidley USA Inc.\nwyatt.garriott@alltech.com\nAlan Keller, Feed & Fertilizer Chief\nIowa Department of Agriculture & Land Stewardship\n1305 East Walnut Street\nDes Moines, Iowa 50319\nalan.keller@iowaagriculture.gov\n______________\n1 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n2 See Section 301(uu) of the FD&C Act [21 U.S.C. § 342(uu)].\n3 See Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B] and 21 CFR 225.1(b)(1).\n4 See Section 512(a)(2)(A) of the FD&C Act [21 U.S.C. § 360b(a)(2)(A)].\n5 See Section 501(a)(6) of the FD&C Act [21 U.S.C. § 351(a)(6)].\n6 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n7 See 21 CFR 558.6 and 21 CFR 558.128.\n8 See 21 CFR Part 507.47.","Ridley USA Inc.","ridley-usa-inc-720800-04032026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fridley-usa-inc-720800-04032026","2026-10-26T08:09:49.713674+00:00","2026-05-12","720800","Animal & Veterinary","Darrell K. Meyer","2026-08-19T04:43:13.574+00:00","VIA EMAIL NO HARD COPY TO FOLLOW","2026-04-03",{"id":217,"raw":218,"subject":223,"body_html":224,"body_text":225,"firm_name":226,"letter_id":227,"created_at":62,"fei_number":19,"letter_url":228,"updated_at":229,"action_type":22,"case_status":23,"posted_date":230,"marcs_cms_no":231,"product_type":232,"closeout_date":19,"issuing_office":222,"recipient_name":233,"body_fetched_at":234,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":235,"medical_device_id":19,"response_letter_date":19},1321,[219,220,221,222,223,13,13,13],"\u003Ctime datetime=\"2024-08-13T13:20:00Z\">08\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-27T04:00:00Z\">06\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaylab-usa-llc-679001-06272024\">Baylab USA, LLC\u003C\u002Fa>","OHT4: Office of Surgical and Infection Control Devices, Office of Product Evaluation and Quality","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ashley Park, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Justin C. Lee, Vice President of Strategic Planning, Development, and Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baylab USA, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2230 Lyndon B Johnson Fwy, Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75234-7331\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>OHT4: Office of Surgical and Infection Control Devices, Office of Product Evaluation and Quality\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS: 679001\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 27, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Park &amp; Mr. Lee:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Dallas, TX on January 24, 2024, to January 31, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the Class II BAYLAB 3-Ply Surgical Mask (BEACON I) (ASTM Level 3 Mask). Your firm also manufactures the ASTM Level 1 Baylab 3-Ply Earloop Face Mask (ASTM Level 1 Mask) and the KN95 Respirator. Information and records gathered prior to, during, and\u002For after the inspection, including information on your website, www.baylabusa.com, reflect that your products are intended for medical use and are to be worn to reduce potential exposure of the user to particulates, bacteria, and\u002For blood or body fluids. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your ASTM Level 1 Mask and KN95 Respirator, and certain versions of your ASTM Level 3 Mask\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The ASTM Level 3 Mask is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the material and intended use without submitting a new premarket notification to FDA as required by section 510(k), 21 U.S.C. § 360(k), and 21 C.F.R. 807.81(a)(3)(i)-(ii). The ASTM Level 1 Mask and KN95 respirator are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>1. Specifically, your ASTM Level 3 Mask in “bay blue” was cleared under 510(k) submission, K212302, for adult use. The Indications for Use (IFU) for the mask, as cleared under K212302 states, in part, that your mask is “intended to be worn to protect both the patient and healthcare personnel from transfer of microorganisms, body fluids and particulate material” and to “reduce the potential exposure to blood and body fluids.”\u003C\u002Fp>\n\n\u003Cp>During the inspection it was revealed that your ASTM Level 3 Mask is offered in multiple colors and in pediatric sizes that were not included in your 510(k) submission. Additionally, a review of your firm’s website, http:\u002F\u002Fwww.baylabusa.com (last accessed June 21, 2024), revealed that your firm is marketing your ASTM Level 3 Mask in colors including “silver surf,” “admiral navy,” “orca black,” “seafoam green,” “sea lavender,” “coral pink,” and “white tide.” Your website also offers the “Kids ASTM Level 3 Mask,” “Anti-Fog ASTM Level 3 Mask,” as well as special edition models with printed logos including, but not limited to, “Breast Cancer Awareness,” “Love,” and “Summer” masks.\u003C\u002Fp>\n\n\u003Cp>The additional colors, materials, and expansion of the user population constitute significant changes or modifications that require a premarket notification. For example, the introduction of new materials, including new colors (colorants) and printed logos, are changes or modifications that could significantly affect the safety or effectiveness of the device in that they may alter the chemistry of the final device. Colorants are known to contain pigments, dyes, additives and\u002For contaminants that may cause adverse effects such as irritation or allergic reactions, especially in very vulnerable pediatric populations. FDA would therefore expect to review additional testing, including biocompatibility testing, in a premarket submission to evaluate the impact of these changes. Furthermore, the change in the user population (i.e., the inclusion of a pediatric population) is a major change in the intended use of the device. FDA would expect to review additional performance data, including, but not limited to, mask fit as well as heavy metal and element analysis, to demonstrate that your mask can be used safely and provide the intended respiratory protection in the pediatric population. This information needs to be reviewed in a premarket submission as required by 21 CFR 878.4040 and 21 CFR 807.81.\u003C\u002Fp>\n\n\u003Cp>2. Specifically, during the inspection, labeling was collected for your ASTM Level 1 Mask and KN95 Respirator. The labeling collected for the ASTM Level 1 Mask included statements claiming, “bacterial filtration efficiency,” “particle filtration efficiency,” and “fluid resistance,” and the label collected for the KN95 respirator contained a statement claiming, “filtration efficiency against solid and water-based particulates.” Additionally, a review of your firm’s website, http:\u002F\u002Fwww.baylabusa.com (last accessed June 21, 2024), revealed that both devices are marketed as providing at least 95% particulate or bacterial filtration efficiency and fluid resistance at 80 mmHg. Both devices are also stated to be “fluid resistant.” The masks are available for purchase on your website in various colors and with various logos. Based on these claims, these products are devices under 21 U.S.C. § 321(h) because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body. The ASTM Level 1 Mask and the KN95 Respirator are therefore adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, 21 C.F.R. 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Adulteration under section 501(h) – Quality System Regulations\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain design controls, as required by 21 CFR § 820.30(a). Specifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines some procedures for design controls (e.g., design planning, inputs, outputs, reviews, verification and validation, and changes), our inspection revealed that your firm has not adequately established and maintained all required design controls. For example, the Quality Management System Manual does not reference or discuss the establishment and maintenance of a design history file (DHF), as required by 21 CFR 820.30(j), and, upon request at the inspection, your firm could not provide a DHF. Further, our inspection revealed that your design was not validated under simulated or actual use conditions and no risk analysis was performed, as required by 21 CFR 820.30(g). Your firm has therefore failed to establish and maintain design controls for the ASTM Level 3 Mask.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain requirements, including quality requirements, that must be met by suppliers, contractors, and consultants as required by 21 CFR § 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Purchasing activities, e.g., purchasing process, purchasing information, and verification of purchased product, it does not reference supplier controls procedures or discuss supplier requirements or evaluation. You do not have documentation of evaluation of your suppliers, contractors, or consultants.\u003C\u002Fp>\n\n\u003Cp>3. Failure to conduct quality audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR § 820.22.\u003C\u002Fp>\n\n\u003Cp>Specifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Internal Audit activities, such as conducting internal audits at planned intervals, at the inspection you were unable to provide documentation that any audits had been conducted.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Monitoring and Measurement, Customer Satisfaction activities such as customer complaints, customer satisfaction and other feedback, and defining methods for collecting and analyzing pertinent information. However, you do not have a complete complaint handling procedures such as determining whether a complaint represents an event which is required to be reported to FDA under Part 803, Medical Device Reporting. We reviewed your complaint log from the period of August 2023 to January 2024. You stated that you did not have a system to track complaints prior to August 2023.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Observations Pertaining to Other Regulations\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Misbranding under Section 502(c) for Failure to Have Compliant Labeling\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) devices do not bear such a UDI.\u003C\u002Fp>\n\n\u003Cp>Specifically, the labels for Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Misbranding under Section 502(t)(2) for Failure to Submit Required Information\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, the Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) device is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting this device. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your ASTM Level 3 Mask and final product labeling reflects your firm’s name, address, and website. Baylab USA, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting this device.\u003C\u002Fp>\n\n\u003Cp>In addition, our inspection also revealed that your firm’s ASTM Level 3 Mask device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written medical device reporting (MDR) procedures as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>Specifically, your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 does not reference MDR procedures. You do not have MDR procedures.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>Our office requests that Baylab USA LLC cease any activities that result in the misbranding or adulteration of the ASTM Level 3 Mask, ASTM Level 1 Mask, and KN95 Respirator, such as the commercial distribution of the devices for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via e-mail to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS case # 679001 when replying. If you have questions regarding the content of this letter, please contact Compliance Officer, Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Binita S. Ashar, MD, MBA, FACS.\u003Cbr>\nDirector\u003Cbr>\nOHT4: Office of Surgical &amp; Infection Control Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3 West\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> More specifically, only the “bay blue” ASTM level 3 Mask was cleared under 510(k) submission. The other colors and versions of the ASTM Level 3 Mask marketed by your firm were not cleared under the 510(k) submission.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAshley Park, President\n\nRecipient Title\n\nJustin C. Lee, Vice President of Strategic Planning, Development, and Operations\n\nBaylab USA, LLC\n\n2230 Lyndon B Johnson Fwy, Ste. 100\n\nDallas, TX 75234-7331\n\nUnited States\n\nIssuing Office:\n\nOHT4: Office of Surgical and Infection Control Devices, Office of Product Evaluation and Quality\n\nUnited States\n\nSecondary Issuing Offices\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS: 679001\n\nJune 27, 2024\n\nDear Ms. Park & Mr. Lee:\n\nDuring an inspection of your firm located in Dallas, TX on January 24, 2024, to January 31, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of the Class II BAYLAB 3-Ply Surgical Mask (BEACON I) (ASTM Level 3 Mask). Your firm also manufactures the ASTM Level 1 Baylab 3-Ply Earloop Face Mask (ASTM Level 1 Mask) and the KN95 Respirator. Information and records gathered prior to, during, and\u002For after the inspection, including information on your website, www.baylabusa.com, reflect that your products are intended for medical use and are to be worn to reduce potential exposure of the user to particulates, bacteria, and\u002For blood or body fluids. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body.\n\nUnapproved Device Violations\n\nOur inspection revealed that your ASTM Level 1 Mask and KN95 Respirator, and certain versions of your ASTM Level 3 Mask1, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The ASTM Level 3 Mask is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with major changes or modifications to the material and intended use without submitting a new premarket notification to FDA as required by section 510(k), 21 U.S.C. § 360(k), and 21 C.F.R. 807.81(a)(3)(i)-(ii). The ASTM Level 1 Mask and KN95 respirator are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\n1. Specifically, your ASTM Level 3 Mask in “bay blue” was cleared under 510(k) submission, K212302, for adult use. The Indications for Use (IFU) for the mask, as cleared under K212302 states, in part, that your mask is “intended to be worn to protect both the patient and healthcare personnel from transfer of microorganisms, body fluids and particulate material” and to “reduce the potential exposure to blood and body fluids.”\n\nDuring the inspection it was revealed that your ASTM Level 3 Mask is offered in multiple colors and in pediatric sizes that were not included in your 510(k) submission. Additionally, a review of your firm’s website, http:\u002F\u002Fwww.baylabusa.com (last accessed June 21, 2024), revealed that your firm is marketing your ASTM Level 3 Mask in colors including “silver surf,” “admiral navy,” “orca black,” “seafoam green,” “sea lavender,” “coral pink,” and “white tide.” Your website also offers the “Kids ASTM Level 3 Mask,” “Anti-Fog ASTM Level 3 Mask,” as well as special edition models with printed logos including, but not limited to, “Breast Cancer Awareness,” “Love,” and “Summer” masks.\n\nThe additional colors, materials, and expansion of the user population constitute significant changes or modifications that require a premarket notification. For example, the introduction of new materials, including new colors (colorants) and printed logos, are changes or modifications that could significantly affect the safety or effectiveness of the device in that they may alter the chemistry of the final device. Colorants are known to contain pigments, dyes, additives and\u002For contaminants that may cause adverse effects such as irritation or allergic reactions, especially in very vulnerable pediatric populations. FDA would therefore expect to review additional testing, including biocompatibility testing, in a premarket submission to evaluate the impact of these changes. Furthermore, the change in the user population (i.e., the inclusion of a pediatric population) is a major change in the intended use of the device. FDA would expect to review additional performance data, including, but not limited to, mask fit as well as heavy metal and element analysis, to demonstrate that your mask can be used safely and provide the intended respiratory protection in the pediatric population. This information needs to be reviewed in a premarket submission as required by 21 CFR 878.4040 and 21 CFR 807.81.\n\n2. Specifically, during the inspection, labeling was collected for your ASTM Level 1 Mask and KN95 Respirator. The labeling collected for the ASTM Level 1 Mask included statements claiming, “bacterial filtration efficiency,” “particle filtration efficiency,” and “fluid resistance,” and the label collected for the KN95 respirator contained a statement claiming, “filtration efficiency against solid and water-based particulates.” Additionally, a review of your firm’s website, http:\u002F\u002Fwww.baylabusa.com (last accessed June 21, 2024), revealed that both devices are marketed as providing at least 95% particulate or bacterial filtration efficiency and fluid resistance at 80 mmHg. Both devices are also stated to be “fluid resistant.” The masks are available for purchase on your website in various colors and with various logos. Based on these claims, these products are devices under 21 U.S.C. § 321(h) because they are intended for use in the diagnosis of diseases or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body. The ASTM Level 1 Mask and the KN95 Respirator are therefore adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency, 21 C.F.R. 807.81(b). The kind of information you need to submit in order to obtain approval or clearance for your device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information you submit and decide whether your product may be legally marketed.\n\nAdulteration under section 501(h) – Quality System Regulations\n\nOur inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain design controls, as required by 21 CFR § 820.30(a). Specifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines some procedures for design controls (e.g., design planning, inputs, outputs, reviews, verification and validation, and changes), our inspection revealed that your firm has not adequately established and maintained all required design controls. For example, the Quality Management System Manual does not reference or discuss the establishment and maintenance of a design history file (DHF), as required by 21 CFR 820.30(j), and, upon request at the inspection, your firm could not provide a DHF. Further, our inspection revealed that your design was not validated under simulated or actual use conditions and no risk analysis was performed, as required by 21 CFR 820.30(g). Your firm has therefore failed to establish and maintain design controls for the ASTM Level 3 Mask.\n\n2. Failure to establish and maintain requirements, including quality requirements, that must be met by suppliers, contractors, and consultants as required by 21 CFR § 820.50(a).\n\nSpecifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Purchasing activities, e.g., purchasing process, purchasing information, and verification of purchased product, it does not reference supplier controls procedures or discuss supplier requirements or evaluation. You do not have documentation of evaluation of your suppliers, contractors, or consultants.\n\n3. Failure to conduct quality audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR § 820.22.\n\nSpecifically, although your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Internal Audit activities, such as conducting internal audits at planned intervals, at the inspection you were unable to provide documentation that any audits had been conducted.\n\n4. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR § 820.198(a).\n\nSpecifically, your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 briefly outlines Monitoring and Measurement, Customer Satisfaction activities such as customer complaints, customer satisfaction and other feedback, and defining methods for collecting and analyzing pertinent information. However, you do not have a complete complaint handling procedures such as determining whether a complaint represents an event which is required to be reported to FDA under Part 803, Medical Device Reporting. We reviewed your complaint log from the period of August 2023 to January 2024. You stated that you did not have a system to track complaints prior to August 2023.\n\nObservations Pertaining to Other Regulations\n\nMisbranding under Section 502(c) for Failure to Have Compliant Labeling\n\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) devices do not bear such a UDI.\n\nSpecifically, the labels for Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\n\nMisbranding under Section 502(t)(2) for Failure to Submit Required Information\n\nIn addition, the Beacon I 3-Ply Earloop Face Mask (ASTM Level 3 Mask) device is misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting this device. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Our inspection revealed that your firm designs the finished product label for your ASTM Level 3 Mask and final product labeling reflects your firm’s name, address, and website. Baylab USA, LLC is therefore a “labeler” within the meaning of 21 CFR 830.3 and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting this device.\n\nIn addition, our inspection also revealed that your firm’s ASTM Level 3 Mask device is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written medical device reporting (MDR) procedures as required by 21 CFR 803.17.\n\nSpecifically, your Quality Management System Manual, Version III, Rev. 11\u002F15\u002F2023 does not reference MDR procedures. You do not have MDR procedures.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\n\nOur office requests that Baylab USA LLC cease any activities that result in the misbranding or adulteration of the ASTM Level 3 Mask, ASTM Level 1 Mask, and KN95 Respirator, such as the commercial distribution of the devices for the uses discussed above.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via e-mail to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov. Refer to CMS case # 679001 when replying. If you have questions regarding the content of this letter, please contact Compliance Officer, Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS.\n\nDirector\n\nOHT4: Office of Surgical & Infection Control Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3 West\n\n__________________________\n\n1 More specifically, only the “bay blue” ASTM level 3 Mask was cleared under 510(k) submission. The other colors and versions of the ASTM Level 3 Mask marketed by your firm were not cleared under the 510(k) submission.","Baylab USA, LLC","baylab-usa-llc-679001-06272024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaylab-usa-llc-679001-06272024","2026-10-26T08:08:01.843887+00:00","2024-08-13","679001","Medical Devices","Ashley Park, President","2026-08-19T23:53:31.468+00:00","2024-06-27",{"id":237,"raw":238,"subject":243,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":184,"fei_number":19,"letter_url":248,"updated_at":249,"action_type":22,"case_status":23,"posted_date":250,"marcs_cms_no":251,"product_type":252,"closeout_date":19,"issuing_office":242,"recipient_name":19,"body_fetched_at":253,"delivery_method":254,"recipient_title":19,"reference_number":255,"action_taken_date":256,"medical_device_id":19,"response_letter_date":19},481,[239,240,241,242,243,13,13,13],"\u003Ctime datetime=\"2025-11-17T05:00:00Z\">11\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-12T05:00:00Z\">11\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmr-vape-usa-llc-719424-11122025\">Mr. Vape USA LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501342\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Mr. Vape USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1833 West Main Street, Suite 110\u002F111\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mesa\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Mr. Vape USA LLC sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: FRUISION JUICE CO SWEET APPLE SUGAR BABY 100ML 6MG.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501342, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501342\n\nProduct:\n\nTobacco\n\nRecipient:\n\nMr. Vape USA LLC\n\n1833 West Main Street, Suite 110\u002F111\n\nMesa, AZ 85201\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 12, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Mr. Vape USA LLC sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: FRUISION JUICE CO SWEET APPLE SUGAR BABY 100ML 6MG.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501342, in your response and direct your response to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Mr. Vape USA LLC","mr-vape-usa-llc-719424-11122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmr-vape-usa-llc-719424-11122025","2026-10-26T08:09:28.551738+00:00","2025-11-17","719424","Tobacco","2026-08-19T14:56:00.68+00:00","VIA UPS and Electronic Mail","ER2501342","2025-11-12",{"id":258,"raw":259,"subject":12,"body_html":263,"body_text":264,"firm_name":265,"letter_id":266,"created_at":267,"fei_number":19,"letter_url":268,"updated_at":269,"action_type":22,"case_status":23,"posted_date":270,"marcs_cms_no":271,"product_type":26,"closeout_date":19,"issuing_office":139,"recipient_name":272,"body_fetched_at":273,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":274,"medical_device_id":19,"response_letter_date":19},836,[260,261,262,139,12,13,13,13],"\u003Ctime datetime=\"2025-06-10T04:00:00Z\">06\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-02T05:00:00Z\">01\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgongora-usa-corp-699609-01022025\">Gongora USA Corp\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jorge G. Abarca\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gongora USA Corp\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>355 K St. Suite F\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chula Vista\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91911-1209\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 02, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 699609\u003C\u002Fp>\u003Cp>Dear Mr. Jorge G. Abarca:\u003C\u002Fp>\u003Cp>From November 14 to November 15, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Gongora USA Corp located at 355 K St. Suite F, Chula Vista, California. We also conducted an inspection between December 1, 2020, to January 13, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for failing to develop an FSVP for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form 483a issued November 15, 2024.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\u003C\u002Fp>\u003Cul>\u003Cli>Fresh Cucumbers from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Fresh White Squash from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Fresh Cue Ball Squash from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # \u003Cstrong>(b)(4)\u003C\u002Fstrong> at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Santiago Gallardo Johnson, Compliance Officer, the Division of Southwest Imports, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Santiago Gallardo Johnson via email at santiago.gallardojohnson@fda.hhs.gov. Please reference CMS # 699609 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Todd Cato\u003Cbr>Program Division Director\u003Cbr>Division of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJorge G. Abarca\n\nRecipient Title\n\nOwner\n\nGongora USA Corp\n\n355 K St. Suite F\n\nChula Vista, CA 91911-1209\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nJanuary 02, 2025\nWARNING LETTER\nRe: CMS # 699609\nDear Mr. Jorge G. Abarca:\nFrom November 14 to November 15, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Gongora USA Corp located at 355 K St. Suite F, Chula Vista, California. We also conducted an inspection between December 1, 2020, to January 13, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for failing to develop an FSVP for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form 483a issued November 15, 2024.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including:\nFresh Cucumbers from (b)(4), located in (b)(4).\nFresh White Squash from (b)(4), located in (b)(4).\nFresh Cue Ball Squash from (b)(4), located in (b)(4).\nYou import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # (b)(4) at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Santiago Gallardo Johnson, Compliance Officer, the Division of Southwest Imports, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Santiago Gallardo Johnson via email at santiago.gallardojohnson@fda.hhs.gov. Please reference CMS # 699609 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nTodd Cato\nProgram Division Director\nDivision of Southwest Imports","Gongora USA Corp","gongora-usa-corp-699609-01022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgongora-usa-corp-699609-01022025","2026-10-26T08:08:48.081029+00:00","2025-06-10","699609","Jorge G. Abarca","2026-08-19T16:41:15.632+00:00","2025-01-02",{"id":276,"raw":277,"subject":12,"body_html":282,"body_text":283,"firm_name":284,"letter_id":285,"created_at":62,"fei_number":19,"letter_url":286,"updated_at":287,"action_type":22,"case_status":23,"posted_date":288,"marcs_cms_no":289,"product_type":26,"closeout_date":19,"issuing_office":281,"recipient_name":290,"body_fetched_at":291,"delivery_method":292,"recipient_title":19,"reference_number":19,"action_taken_date":293,"medical_device_id":19,"response_letter_date":19},1141,[278,279,280,281,12,13,13,13],"\u003Ctime datetime=\"2024-12-10T14:20:00Z\">12\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-04T05:00:00Z\">11\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwanabana-usa-llc-680548-11042024\">WANABANA USA LLC\u003C\u002Fa>","Division of Southeast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>EXPRESS DELIVERY SIGNATURE REQUEST\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Francisco Pena Cordovez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>WANABANA USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2113 W. 30th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jacksonville\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32209-3634\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 4, 2024\u003C\u002Fp>\u003Cp>Re: CMS # 680548\u003C\u002Fp>\u003Cp>Dear Mr. Francisco Pena Cordovez:\u003C\u002Fp>\u003Cp>\u003Cbr>On February 21 through March 7, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of WanaBana USA LLC located at 2113 W. 30th St., Jacksonville, FL 32209-3634. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L. The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA's FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>The inspection was initiated in response to a multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public), manufactured by your foreign supplier Austrofood S.A.S. (Austrofood) of Ecuador. Apple cinnamon fruit puree pouches were subject to a Class 1 recall, initiated on October 29, 2023. The recall was in response to finished product samples of Wanabana brand RTE apple cinnamon fruit puree packed in flexible pouches, collected by North Carolina Department of Health and Human Services (NCDHHS) found to contain extremely high concentrations of lead. You imported Wanabana brand apple cinnamon fruit puree pouches from your foreign supplier, Austrofood. We placed apple cinnamon fruit puree pouches from your foreign supplier on Import Alert #99-42, \"Detention Without Physical Examination (DWPE) of Foods Due to Heavy Metal (Toxic Element) Contamination,\" on November 6, 2023. You may view this alert at: \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_1167.html.\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_1167.html.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>FDA and state partners also collected and analyzed additional product samples of fruit puree and apple sauce pouches manufactured by your foreign supplier Austrofood. FDA, the Maryland Department of Health (MDH), and the North Carolina Department of Agriculture &amp; Consumer Services (NCDA&amp;CS) detected extremely high concentrations of lead in WanaBana Apple Cinnamon Fruit Puree pouches imported by your firm. FDA has reviewed and supports the MDH and NCDA&amp;CS analytical findings. Specifically:&nbsp;\u003C\u002Fp>\u003Cp>■ 2.18 parts per million (ppm) lead was detected in FDA Sample 1234871, 6.43 ppm lead was detected in MDH Sample FC2400004901, and 2.16 - 3.19 ppm lead was detected in NCDA&amp;CS Samples FDC0222755 - FDC0222760 of WanaBana Apple Cinnamon Fruit Puree pouches collected from Dollar Tree stores.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have received your response to the FDA 483a, issued on March 20, 2024, describing corrective actions taken and planned by your firm and we address your response below.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulations are as follows:\u003C\u002Fp>\u003Cp>1. You did not conduct a hazard analysis to identify and evaluate, based on experience, illness data, scientific reports, and other information, known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control for the apple cinnamon puree product you import from your foreign supplier, Austrofood, per 21 CFR 1.504(a). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including pesticide residues), and physical hazards (21 CFR 1.504(b)(1)). Specifically, your hazard analysis for your fruit purees and smoothies from your foreign supplier, Austrofood did not identify and evaluate the potential chemical hazard of heavy metals, specifically lead, to determine whether the hazard requires a control per 21 CFR 1.504(a).\u003C\u002Fp>\u003Cp>During our inspection you provided our investigator with your \"FSVP Program Version 1\" dated September 8, 2021 for your fruit purees and smoothies noting intended consumers as \"general public aged over 12 months\" and which included your hazard analysis. Your hazard analysis did not consider the chemical hazard of heavy metals, specifically lead, as a potential food safety hazard for the apple cinnamon fruit puree you import from your foreign supplier, Austrofood. Subsequently, you did not consider this hazard when evaluating your foreign supplier or determining appropriate verification activities for the foods you imported from your foreign supplier, which were subject to the recall that was initiated October 29, 2023.\u003C\u002Fp>\u003Cp>During our inspection you also provided your revised FSVP including your hazard analysis dated January 10, 2024, for your apple cinnamon fruit puree from your foreign supplier, Austrofood. You also provided a written response, which we received on May 6, 2024, in which you submitted your FSVP Version 3 for Fruit and vegetable purees in a pouch from Austrofood; an FSVP record #1, Foreign Supplier Hazard Analysis Review and Evaluation, dated April 10, 2024; and FSVP record #3, Foreign Supplier Verification Activity(s), dated April 10, 2024. We acknowledge that your revised hazard analysis dated January 10, 2024, and your revised hazard analysis provided in your May 6, 2024, response both identified the chemical hazard of \"heavy metals (arsenic, lead, chromium, cadmium, copper)\" as a potential hazard in your fruit and vegetable purees in a pou\u003Ca>ch.\u003C\u002Fa> These revisions were dated after you imported these foods from your foreign supplier and after FDA found high levels of lead in your apple cinnamon puree imported from your supplier, Austrofood, S.A.S. We will continue assessing the adequacy of your corrective actions and verification activities at our next inspection.\u003C\u002Fp>\u003Cp>2. Your foreign supplier verification activities did not provide assurance that the hazards requiring a control in the food you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). You did not, based on the determination made in accordance with 21 CFR 1.506(d), conduct and document, or obtain documentation of, one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e).\u003C\u002Fp>\u003Cp>During our inspection you provided your FSVP, dated August 9, 2021, for your apple cinnamon puree from foreign supplier, Austrofood. You told our investigator that this was the FSVP you implemented for the products you imported prior to the Class 1 recall initiated in October 2023. Your FSVP included your six-page \"Form 3 - FSVP Supplier Verification Activity Form\" which shows that you determined your verification activities to be a \"3rd party audit\" and a Review of \u003Cstrong>(b)(4)\u003C\u002Fstrong> relevant to food safety\" conducted \u003Cstrong>(b)(4)\u003C\u002Fstrong> (page 3). You also provided the audit report (10\u002F18\u002F2021-10\u002F20\u002F2021) referenced in your onsite audit review (page 4) and the Quality Certificate (not dated) referenced in your \"Review of food safety records\" (page 5). Your approval is dated 10\u002F10\u002F2022 (page 6). You also provided a \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit of your supplier, Austrofood from 2023. However, prior to importing your apple cinnamon puree in February 27, 2023, you did not conduct and document your supplier verification activity, specifically \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit of your foreign supplier in 2022 as required by as required by 21 CFR 1.506(e). Additionally, the Quality Certificate and translation you provided shows testing results for samples of the cinnamon powder used by your foreign supplier. This record of sampling and testing includes results for heavy metals arsenic(&lt;1.0 mg\u002Fkg) and lead (&lt;2.0 mg\u002Fkg) but does not include the test(s) conducted (including the analytical method(s) used), the date(s) on which the test(s) were conducted, or the date of the report of the testing, as required by 21 CFR 1.506(e)(1)(ii). You imported your apple cinnamon puree from Austrofood based on the FSVP records described above, a product which was subsequently subject to a Class 1 recall in October 2023.\u003C\u002Fp>\u003Cp>We acknowledge that you provided your Form #4 FSVP Supplier Reevaluation form for Austrofood S.A.S. in your Form 483a response dated April 10, 2024, and you stated that your current verification activities included Laboratory analysis of heavy metals for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of finished product that contains spices as ingredients. While you provided a Quality certificate for cinnamon, as described above, you have not provided records or documentation of heavy metal analysis in the finished product of apple cinnamon puree.\u003C\u002Fp>\u003Cp>3. You must promptly reevaluate a foreign supplier's performance or the risk posed by a food when you became aware of new information about the foreign supplier's performance or the risk posed by a food, as required by 21 CFR 1.505(c)(1). If you determine that the concerns associated with importing a food from a foreign supplier have changed, you must promptly determine (and document) whether it is appropriate to continue to import the food from the foreign supplier and whether the supplier verification activities conducted under § 1.506 need to be changed. However, you were notified in October 2023 of the hazard associated with your apple cinnamon puree imported from Austrofood S.A.S. but you did not conduct your reevaluation of your foreign supplier until January 2024, over 3 months later. Furthermore, you provided your \"Form #4 Supplier Reevaluation on which you indicate \"The foreign supplier passed the most recent third-party food safety audit (include score, results and date).\" This is followed in part by \"GS\u003Ca>FI\u003C\u002Fa>, \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" and \"FDA Audit - 4 nonconformities, 12\u002F4\u002F20\u003Ca>24\u003C\u002Fa> \u003Ca>to\u003C\u002Fa> 12\u002F13\u002F2024.\" Your assessment in your January 16, 2024 reevaluation of your supplier shows that you relied on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Audit (Octob\u003Ca>er\u003C\u002Fa> 24-2\u003Ca>6,\u003C\u002Fa> 2023), which was conducted before you became aware of the recall on October 27, 2023 (per your statements during the inspection) and before corrections would have been made by the foreign supplier, Austrofood S.A.S. Additionally, your assessment did not appropriately consider the FDA inspection conducted at Austrofood S.A.S, which resulted in four non-conformities on December 14, 2023, after the Class I Recall. FDA finds your reevaluation was neither conducted promptly, nor was your determination to continue with importing apple cinnamon puree from Austrofood S.A.S appropriate.\u003C\u002Fp>\u003Cp>We acknowledge in your written response dated May 6, 2024 that your updated Procedure for reevaluating activities of foreign suppliers states that you will re-evaluate a foreign supplier within \u003Cstrong>(b)(4) \u003C\u002Fstrong>if the foreign suppler is associated with a \"recall, import alerts, etc.\" The adequacy of this corrective action will be verified at the next inspection.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 80l(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\u003Cp>You are required to conduct a written hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard analysis must identify known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including heavy metals, such as lead), and physical hazards (21 CFR 1.504(b)(1)). Your hazard analysis must include an evaluation of the identified hazards to assess the probability that the hazard will occur in the absence of controls and the severity of the illness or injury if the hazard were to occur (21 CFR 1.504(c)(1)). Your hazard analysis must be written regardless of its outcome, in accordance with 21 CFR 1.504(a). Your hazard analysis must also include known or reasonably foreseeable hazards that may be present in a food if it the hazard occurs naturally, if the hazard is unintentionally introduced, or if the hazard may be intentionally introduced for purposes of economic gain, per 21 CFR 1.504(b)(2). Finally, your hazard evaluation must also consider, among other things, the formulation of the food, the raw materials and other ingredients, and any other relevant factors on the safety of the finished food for the intended consumer.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Allison McGloin, Compliance Officer, Division of Southeast Imports, 550 Main Street, Suite #4-930, Cincinnati, OH 45202. If you have any questions regarding this letter, you may contact Compliance Officer Allison McGloin via email at Allison.McGloin@fda.hhs.gov. Please reference CMS# 680548 on any documents or reco\u003Ca>rds you\u003C\u002Fa> \u003Ca>provide\u003C\u002Fa> to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Ruth Dixon\u003Cbr>Program Division Director\u003Cbr>Division of Southeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nEXPRESS DELIVERY SIGNATURE REQUEST\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nFrancisco Pena Cordovez\n\nRecipient Title\n\nPresident\n\nWANABANA USA LLC\n\n2113 W. 30th St.\n\nJacksonville, FL 32209-3634\n\nUnited States\n\nIssuing Office:\n\nDivision of Southeast Imports\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nNovember 4, 2024\nRe: CMS # 680548\nDear Mr. Francisco Pena Cordovez:\n\nOn February 21 through March 7, 2024, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of WanaBana USA LLC located at 2113 W. 30th St., Jacksonville, FL 32209-3634. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L. The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA's FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&C Act.\nThe inspection was initiated in response to a multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public), manufactured by your foreign supplier Austrofood S.A.S. (Austrofood) of Ecuador. Apple cinnamon fruit puree pouches were subject to a Class 1 recall, initiated on October 29, 2023. The recall was in response to finished product samples of Wanabana brand RTE apple cinnamon fruit puree packed in flexible pouches, collected by North Carolina Department of Health and Human Services (NCDHHS) found to contain extremely high concentrations of lead. You imported Wanabana brand apple cinnamon fruit puree pouches from your foreign supplier, Austrofood. We placed apple cinnamon fruit puree pouches from your foreign supplier on Import Alert #99-42, \"Detention Without Physical Examination (DWPE) of Foods Due to Heavy Metal (Toxic Element) Contamination,\" on November 6, 2023. You may view this alert at: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fimportalert_1167.html.\nFDA and state partners also collected and analyzed additional product samples of fruit puree and apple sauce pouches manufactured by your foreign supplier Austrofood. FDA, the Maryland Department of Health (MDH), and the North Carolina Department of Agriculture & Consumer Services (NCDA&CS) detected extremely high concentrations of lead in WanaBana Apple Cinnamon Fruit Puree pouches imported by your firm. FDA has reviewed and supports the MDH and NCDA&CS analytical findings. Specifically:\n■ 2.18 parts per million (ppm) lead was detected in FDA Sample 1234871, 6.43 ppm lead was detected in MDH Sample FC2400004901, and 2.16 - 3.19 ppm lead was detected in NCDA&CS Samples FDC0222755 - FDC0222760 of WanaBana Apple Cinnamon Fruit Puree pouches collected from Dollar Tree stores.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have received your response to the FDA 483a, issued on March 20, 2024, describing corrective actions taken and planned by your firm and we address your response below.\nYour significant violations of the FSVP regulations are as follows:\n1. You did not conduct a hazard analysis to identify and evaluate, based on experience, illness data, scientific reports, and other information, known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control for the apple cinnamon puree product you import from your foreign supplier, Austrofood, per 21 CFR 1.504(a). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including pesticide residues), and physical hazards (21 CFR 1.504(b)(1)). Specifically, your hazard analysis for your fruit purees and smoothies from your foreign supplier, Austrofood did not identify and evaluate the potential chemical hazard of heavy metals, specifically lead, to determine whether the hazard requires a control per 21 CFR 1.504(a).\nDuring our inspection you provided our investigator with your \"FSVP Program Version 1\" dated September 8, 2021 for your fruit purees and smoothies noting intended consumers as \"general public aged over 12 months\" and which included your hazard analysis. Your hazard analysis did not consider the chemical hazard of heavy metals, specifically lead, as a potential food safety hazard for the apple cinnamon fruit puree you import from your foreign supplier, Austrofood. Subsequently, you did not consider this hazard when evaluating your foreign supplier or determining appropriate verification activities for the foods you imported from your foreign supplier, which were subject to the recall that was initiated October 29, 2023.\nDuring our inspection you also provided your revised FSVP including your hazard analysis dated January 10, 2024, for your apple cinnamon fruit puree from your foreign supplier, Austrofood. You also provided a written response, which we received on May 6, 2024, in which you submitted your FSVP Version 3 for Fruit and vegetable purees in a pouch from Austrofood; an FSVP record #1, Foreign Supplier Hazard Analysis Review and Evaluation, dated April 10, 2024; and FSVP record #3, Foreign Supplier Verification Activity(s), dated April 10, 2024. We acknowledge that your revised hazard analysis dated January 10, 2024, and your revised hazard analysis provided in your May 6, 2024, response both identified the chemical hazard of \"heavy metals (arsenic, lead, chromium, cadmium, copper)\" as a potential hazard in your fruit and vegetable purees in a pouch. These revisions were dated after you imported these foods from your foreign supplier and after FDA found high levels of lead in your apple cinnamon puree imported from your supplier, Austrofood, S.A.S. We will continue assessing the adequacy of your corrective actions and verification activities at our next inspection.\n2. Your foreign supplier verification activities did not provide assurance that the hazards requiring a control in the food you import have been significantly minimized or prevented, as required by 21 CFR 1.506(c). You did not, based on the determination made in accordance with 21 CFR 1.506(d), conduct and document, or obtain documentation of, one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter, as required by 21 CFR 1.506(e).\nDuring our inspection you provided your FSVP, dated August 9, 2021, for your apple cinnamon puree from foreign supplier, Austrofood. You told our investigator that this was the FSVP you implemented for the products you imported prior to the Class 1 recall initiated in October 2023. Your FSVP included your six-page \"Form 3 - FSVP Supplier Verification Activity Form\" which shows that you determined your verification activities to be a \"3rd party audit\" and a Review of (b)(4) relevant to food safety\" conducted (b)(4) (page 3). You also provided the audit report (10\u002F18\u002F2021-10\u002F20\u002F2021) referenced in your onsite audit review (page 4) and the Quality Certificate (not dated) referenced in your \"Review of food safety records\" (page 5). Your approval is dated 10\u002F10\u002F2022 (page 6). You also provided a (b)(4) audit of your supplier, Austrofood from 2023. However, prior to importing your apple cinnamon puree in February 27, 2023, you did not conduct and document your supplier verification activity, specifically (b)(4) audit of your foreign supplier in 2022 as required by as required by 21 CFR 1.506(e). Additionally, the Quality Certificate and translation you provided shows testing results for samples of the cinnamon powder used by your foreign supplier. This record of sampling and testing includes results for heavy metals arsenic(\u003C1.0 mg\u002Fkg) and lead (\u003C2.0 mg\u002Fkg) but does not include the test(s) conducted (including the analytical method(s) used), the date(s) on which the test(s) were conducted, or the date of the report of the testing, as required by 21 CFR 1.506(e)(1)(ii). You imported your apple cinnamon puree from Austrofood based on the FSVP records described above, a product which was subsequently subject to a Class 1 recall in October 2023.\nWe acknowledge that you provided your Form #4 FSVP Supplier Reevaluation form for Austrofood S.A.S. in your Form 483a response dated April 10, 2024, and you stated that your current verification activities included Laboratory analysis of heavy metals for (b)(4) of finished product that contains spices as ingredients. While you provided a Quality certificate for cinnamon, as described above, you have not provided records or documentation of heavy metal analysis in the finished product of apple cinnamon puree.\n3. You must promptly reevaluate a foreign supplier's performance or the risk posed by a food when you became aware of new information about the foreign supplier's performance or the risk posed by a food, as required by 21 CFR 1.505(c)(1). If you determine that the concerns associated with importing a food from a foreign supplier have changed, you must promptly determine (and document) whether it is appropriate to continue to import the food from the foreign supplier and whether the supplier verification activities conducted under § 1.506 need to be changed. However, you were notified in October 2023 of the hazard associated with your apple cinnamon puree imported from Austrofood S.A.S. but you did not conduct your reevaluation of your foreign supplier until January 2024, over 3 months later. Furthermore, you provided your \"Form #4 Supplier Reevaluation on which you indicate \"The foreign supplier passed the most recent third-party food safety audit (include score, results and date).\" This is followed in part by \"GSFI, (b)(4)\" and \"FDA Audit - 4 nonconformities, 12\u002F4\u002F2024 to 12\u002F13\u002F2024.\" Your assessment in your January 16, 2024 reevaluation of your supplier shows that you relied on the (b)(4) Audit (October 24-26, 2023), which was conducted before you became aware of the recall on October 27, 2023 (per your statements during the inspection) and before corrections would have been made by the foreign supplier, Austrofood S.A.S. Additionally, your assessment did not appropriately consider the FDA inspection conducted at Austrofood S.A.S, which resulted in four non-conformities on December 14, 2023, after the Class I Recall. FDA finds your reevaluation was neither conducted promptly, nor was your determination to continue with importing apple cinnamon puree from Austrofood S.A.S appropriate.\nWe acknowledge in your written response dated May 6, 2024 that your updated Procedure for reevaluating activities of foreign suppliers states that you will re-evaluate a foreign supplier within (b)(4) if the foreign suppler is associated with a \"recall, import alerts, etc.\" The adequacy of this corrective action will be verified at the next inspection.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 80l(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nAdditionally, we offer the following comment:\nYou are required to conduct a written hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard analysis must identify known or reasonably foreseeable hazards for each type of food you import to determine whether there are any hazards requiring a control (21 CFR 1.504(a)). The analysis of the known or reasonably foreseeable hazards in each food must include biological hazards, chemical hazards (including heavy metals, such as lead), and physical hazards (21 CFR 1.504(b)(1)). Your hazard analysis must include an evaluation of the identified hazards to assess the probability that the hazard will occur in the absence of controls and the severity of the illness or injury if the hazard were to occur (21 CFR 1.504(c)(1)). Your hazard analysis must be written regardless of its outcome, in accordance with 21 CFR 1.504(a). Your hazard analysis must also include known or reasonably foreseeable hazards that may be present in a food if it the hazard occurs naturally, if the hazard is unintentionally introduced, or if the hazard may be intentionally introduced for purposes of economic gain, per 21 CFR 1.504(b)(2). Finally, your hazard evaluation must also consider, among other things, the formulation of the food, the raw materials and other ingredients, and any other relevant factors on the safety of the finished food for the intended consumer.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Allison McGloin, Compliance Officer, Division of Southeast Imports, 550 Main Street, Suite #4-930, Cincinnati, OH 45202. If you have any questions regarding this letter, you may contact Compliance Officer Allison McGloin via email at Allison.McGloin@fda.hhs.gov. Please reference CMS# 680548 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\nSincerely,\n\u002Fs\u002F\nRuth Dixon\nProgram Division Director\nDivision of Southeast Imports","WANABANA USA LLC","wanabana-usa-llc-680548-11042024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwanabana-usa-llc-680548-11042024","2026-10-26T08:10:30.349172+00:00","2024-12-10","680548","Francisco Pena Cordovez","2026-08-19T17:40:07.529+00:00","VIA EMAIL AND UNITED PARCEL SERVICE EXPRESS DELIVERY SIGNATURE REQUEST","2024-11-04",{"id":295,"raw":296,"subject":12,"body_html":301,"body_text":302,"firm_name":303,"letter_id":304,"created_at":105,"fei_number":19,"letter_url":305,"updated_at":306,"action_type":22,"case_status":23,"posted_date":307,"marcs_cms_no":308,"product_type":26,"closeout_date":19,"issuing_office":139,"recipient_name":309,"body_fetched_at":310,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":311,"medical_device_id":19,"response_letter_date":19},2307,[297,298,299,300,12,13,13,13],"\u003Ctime datetime=\"2022-12-06T14:20:00Z\">12\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-07T05:00:00Z\">11\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmanzela-usa-llc-642268-11072022\">Manzela USA, LLC\u003C\u002Fa>"," Division of Southwest Imports ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Andres Venado\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Manzela USA, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1300 E. Hackberry Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McAllen\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78501-5748\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Southwest Imports \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 7, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 642268\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Andres Venado:\u003C\u002Fp>\n\n\u003Cp>On June 15, 2022 through June 24, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Manzela USA, LLC located at 1300 E. Hackberry Ave., McAllen, TX 78501. We also conducted an inspection on May 13, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response dated June 28, 2022, and we address your response below.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated you are currently working to correct the FSVPs you have and to create FSVPs that are missing. We are unable to evaluate the adequacy of your response because you did not provide any&nbsp;supporting documentation or describe specific steps that you have taken to comply with the FSVP regulation.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:&nbsp;\u003C\u002Fp>\n\n\u003Cp>1.&nbsp; You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the following foods you import:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Com Chips imported from foreign supplier Manzela S.A. de C.V., located in Mexico\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Candy imported from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Peanuts imported from foreign supplier Manzela S.A. de C.V., located in Mexico\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2.&nbsp; You did not meet the requirement to evaluate your foreign supplier's performance and the risk posed by the food, and to approve your foreign supplier on the basis of this evaluation, in accordance with 21 CPR 1.505. Specifically, during our inspection, you provided a document titled, \"Food Safety Plan, Manzela USA,\" which you described as an FSVP for Haba Enchilada (Fava Bean with Chili Seasoning) imported from Manzela, S.A. De C.V., Mexico. The document includes a general description of your facility, contacts for your food safety team, and what appears to be a food safety plan for your Haba Enchilada, including a hazard analysis and tables summarizing process preventive controls, food allergen preventive controls, and a recall plan. The document also contains incomplete sections titled, \"re-analysis of food safety plan,\" and \"signature and date.\" Although some of the activities in the preventive controls sections of this document appear to be associated with hazards identified in the hazard analysis, there is no description or explanation as to who or which entity will conduct these activities, e.g., the importer or the foreign supplier. Furthermore, there is no description of how the information in this document relates to your foreign supplier's performance, including procedures, processes, and practices related to the safety of the food; or applicable food safety regulations and information relevant to the foreign supplier's compliance with those regulations. The document does not include your evaluation of the foreign supplier's performance and the risk posed by the food, as required by 1.505(a), or approval of the foreign supplier, as required by 1.505(b).\u003C\u002Fp>\n\n\u003Cp>3.&nbsp; You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506 for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for your Haba Enchilada imported from Manzela S.A. de C.V., located in Mexico. While you provided a document titled, \"Food Safety Plan, Manzela USA,\" which you described as an FSVP for Haba Enchilada, the document does not include information related to your determination of appropriate verification activities or verification activities that you conducted or reviewed. Furthermore, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), and you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d). Your written response dated June 28, 2022 did not provide any additional documentation related to your foreign supplier, Manzela S.A. de C.V.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpru.1 L.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 38l(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert# 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms%20ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Emmanuel Dominguez, Compliance Officer, Division of Southwest Imports, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact Emmanuel Dominguez via email at Emmanuel.Dominguez@fda.hhs.gov. Please reference CMS # 642268 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDirector, Southwest Imports\u003Cbr>\nOne Main Place\u003Cbr>\n1201 Main Street, Suite 7200\u003Cbr>\nDallas, TX 75202\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Andres Venado\n\nRecipient Title\n\nOwner\n\nManzela USA, LLC\n\n1300 E. Hackberry Ave.\n\nMcAllen, TX 78501-5748\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nNovember 7, 2022\n\nWARNING LETTER\n\nRe: CMS # 642268\n\nDear Mr. Andres Venado:\n\nOn June 15, 2022 through June 24, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Manzela USA, LLC located at 1300 E. Hackberry Ave., McAllen, TX 78501. We also conducted an inspection on May 13, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response dated June 28, 2022, and we address your response below.\n\nIn your response, you stated you are currently working to correct the FSVPs you have and to create FSVPs that are missing. We are unable to evaluate the adequacy of your response because you did not provide any supporting documentation or describe specific steps that you have taken to comply with the FSVP regulation.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the following foods you import:\n\nCom Chips imported from foreign supplier Manzela S.A. de C.V., located in Mexico\n\n(b)(4) Candy imported from foreign supplier (b)(4) located in (b)(4)\n\nPeanuts imported from foreign supplier Manzela S.A. de C.V., located in Mexico\n\n2. You did not meet the requirement to evaluate your foreign supplier's performance and the risk posed by the food, and to approve your foreign supplier on the basis of this evaluation, in accordance with 21 CPR 1.505. Specifically, during our inspection, you provided a document titled, \"Food Safety Plan, Manzela USA,\" which you described as an FSVP for Haba Enchilada (Fava Bean with Chili Seasoning) imported from Manzela, S.A. De C.V., Mexico. The document includes a general description of your facility, contacts for your food safety team, and what appears to be a food safety plan for your Haba Enchilada, including a hazard analysis and tables summarizing process preventive controls, food allergen preventive controls, and a recall plan. The document also contains incomplete sections titled, \"re-analysis of food safety plan,\" and \"signature and date.\" Although some of the activities in the preventive controls sections of this document appear to be associated with hazards identified in the hazard analysis, there is no description or explanation as to who or which entity will conduct these activities, e.g., the importer or the foreign supplier. Furthermore, there is no description of how the information in this document relates to your foreign supplier's performance, including procedures, processes, and practices related to the safety of the food; or applicable food safety regulations and information relevant to the foreign supplier's compliance with those regulations. The document does not include your evaluation of the foreign supplier's performance and the risk posed by the food, as required by 1.505(a), or approval of the foreign supplier, as required by 1.505(b).\n\n3. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506 for the products you import. Specifically, you did not document your determination or performance of appropriate supplier verification activities for your Haba Enchilada imported from Manzela S.A. de C.V., located in Mexico. While you provided a document titled, \"Food Safety Plan, Manzela USA,\" which you described as an FSVP for Haba Enchilada, the document does not include information related to your determination of appropriate verification activities or verification activities that you conducted or reviewed. Furthermore, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), and you did not document your determination of the appropriate supplier verification activity in accordance with 21 CFR 1.506(d). Your written response dated June 28, 2022 did not provide any additional documentation related to your foreign supplier, Manzela S.A. de C.V.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpru.1 L.\n\n(b)(3)(A)\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 38l(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert# 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Emmanuel Dominguez, Compliance Officer, Division of Southwest Imports, 216 W. Village Blvd., Suite 107, Laredo, TX 78041. If you have any questions regarding this letter, you may contact Emmanuel Dominguez via email at Emmanuel.Dominguez@fda.hhs.gov. Please reference CMS # 642268 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDirector, Southwest Imports\n\nOne Main Place\n\n1201 Main Street, Suite 7200\n\nDallas, TX 75202","Manzela USA, LLC","manzela-usa-llc-642268-11072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmanzela-usa-llc-642268-11072022","2026-10-26T08:09:20.066049+00:00","2022-12-06","642268","Mr. Andres Venado","2026-08-20T01:23:24.705+00:00","2022-11-07",{"id":313,"raw":314,"subject":320,"body_html":321,"body_text":322,"firm_name":323,"letter_id":324,"created_at":105,"fei_number":19,"letter_url":325,"updated_at":326,"action_type":22,"case_status":86,"posted_date":307,"marcs_cms_no":327,"product_type":26,"closeout_date":328,"issuing_office":329,"recipient_name":330,"body_fetched_at":331,"delivery_method":332,"recipient_title":19,"reference_number":333,"action_taken_date":334,"medical_device_id":19,"response_letter_date":19},2304,[297,315,316,317,318,13,319,13],"\u003Ctime datetime=\"2022-09-23T04:00:00Z\">09\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-09232022\">Saffron USA LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East IV ","Unapproved New Drugs\u002FMisbranded \u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-01092023\">\u003Ctime datetime=\"2023-01-17T05:00:00Z\">01\u002F17\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>17-HAFE4-WL-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Farangis Sedaghat\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Saffron USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>504 Spring Island Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Orlando\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32828\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ftsedaghat@yahoo.com\"> ftsedaghat@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East IV \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 23, 2022\u003Cbr>\n\u003Cbr>\nDear Ms. Sedaghat:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fsaffronusa.com in September 2022 and has determined that you take orders there for the products Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>1. Product: Allergy Blend\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Allergy Blend and under Health Benefits, your webpage shows:\u003Cbr>\n- Product name “Allergy Blend”\u003Cbr>\n- “A natural blend for Allergy relief”\u003Cbr>\n- “Upper respiratory tract infections”\u003Cbr>\n- “Coughs, Bronchitis”\u003Cbr>\n- “Asthma”\u003C\u002Fp>\n\n\u003Cp>2. Product: Chamomile Tea Petals\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Chamomile Tea Petals under Health Benefits, your webpage shows:\u003Cbr>\n- “Treating diabetes”\u003Cbr>\n- “Slowing or preventing osteoporosis”\u003Cbr>\n- “Reducing inflammation”\u003Cbr>\n- “Cancer”\u003Cbr>\n- “[T]reating cold symptoms”\u003C\u002Fp>\n\n\u003Cp>3. Product: Diabetic Support Blend\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Diabetic Support Blend and under Health Benefits, your webpage shows:\u003Cbr>\n- Product name “Diabetic Support Blend”\u003Cbr>\n- “A natural blend to help combat Diabetic”\u003Cbr>\n- “Have Cancer-Fighting Properties”\u003Cbr>\n- “Decrease Cholesterol Levels…”\u003C\u002Fp>\n\n\u003Cp>4. Product: Orange Blast Tea\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Orange Blast Tea under Health Benefits, your webpage shows:\u003Cbr>\n- “Prevents skin damage.”\u003Cbr>\n- “Keeps blood pressure under check.”\u003Cbr>\n- “Lowers cholesterol.”\u003Cbr>\n- “Controls blood sugar level.”\u003Cbr>\n- “Lowers the risk of cancer.”\u003C\u002Fp>\n\n\u003Cp>5. Product: “Saffron Loose Tea”\u003C\u002Fp>\n\n\u003Cp>On your product website https:\u002F\u002Fsaffronusa.com for Saffron Loose Tea under Health Benefits, your webpage shows:\u003Cbr>\n- “Fights Anxiety”\u003Cbr>\n- “Cancer prevention”\u003Cbr>\n- “Help insomnia”\u003C\u002Fp>\n\n\u003Cp>Your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon A. Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to email address: orahafeast4firmresponses@fda.hhs.gov . Please ensure your firm name, Firm Establishment Identifier (FEI) and establishment address are included in the correspondence. If you have any questions regarding this letter, please contact Ms. Gina Eng, Compliance Officer, at (561) 416-1065 ext. 1114 or via email at Gina.Eng@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director | FDA San Juan District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations\u003Cbr>\nEast Division 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n17-HAFE4-WL-07\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Farangis Sedaghat\n\nRecipient Title\n\nManager\n\nSaffron USA LLC\n\n504 Spring Island Way\n\nOrlando, FL 32828\n\nUnited States\n\nftsedaghat@yahoo.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nWARNING LETTER\n\nSeptember 23, 2022\n\nDear Ms. Sedaghat:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fsaffronusa.com in September 2022 and has determined that you take orders there for the products Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n1. Product: Allergy Blend\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Allergy Blend and under Health Benefits, your webpage shows:\n\n- Product name “Allergy Blend”\n\n- “A natural blend for Allergy relief”\n\n- “Upper respiratory tract infections”\n\n- “Coughs, Bronchitis”\n\n- “Asthma”\n\n2. Product: Chamomile Tea Petals\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Chamomile Tea Petals under Health Benefits, your webpage shows:\n\n- “Treating diabetes”\n\n- “Slowing or preventing osteoporosis”\n\n- “Reducing inflammation”\n\n- “Cancer”\n\n- “[T]reating cold symptoms”\n\n3. Product: Diabetic Support Blend\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Diabetic Support Blend and under Health Benefits, your webpage shows:\n\n- Product name “Diabetic Support Blend”\n\n- “A natural blend to help combat Diabetic”\n\n- “Have Cancer-Fighting Properties”\n\n- “Decrease Cholesterol Levels…”\n\n4. Product: Orange Blast Tea\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Orange Blast Tea under Health Benefits, your webpage shows:\n\n- “Prevents skin damage.”\n\n- “Keeps blood pressure under check.”\n\n- “Lowers cholesterol.”\n\n- “Controls blood sugar level.”\n\n- “Lowers the risk of cancer.”\n\n5. Product: “Saffron Loose Tea”\n\nOn your product website https:\u002F\u002Fsaffronusa.com for Saffron Loose Tea under Health Benefits, your webpage shows:\n\n- “Fights Anxiety”\n\n- “Cancer prevention”\n\n- “Help insomnia”\n\nYour Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to the Food and Drug Administration, attention to: Mr. Ramon A. Hernández, District Director, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. You may email a copy of your response with appropriate attachments to email address: orahafeast4firmresponses@fda.hhs.gov . Please ensure your firm name, Firm Establishment Identifier (FEI) and establishment address are included in the correspondence. If you have any questions regarding this letter, please contact Ms. Gina Eng, Compliance Officer, at (561) 416-1065 ext. 1114 or via email at Gina.Eng@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director | FDA San Juan District\n\nProgram Division Director\n\nOffice of Human and Animal Food\n\nOperations\n\nEast Division 4","Saffron USA LLC","saffron-usa-llc-629821-09232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsaffron-usa-llc-629821-09232022","2026-10-26T08:09:52.690735+00:00","629821","2023-01-17","Division of Human and Animal Food Operations East IV","Ms. Farangis Sedaghat","2026-08-20T01:23:29.186+00:00","VIA Electronic Mail","17-HAFE4-WL-07","2022-09-23",{"id":336,"raw":337,"subject":223,"body_html":343,"body_text":344,"firm_name":345,"letter_id":346,"created_at":105,"fei_number":19,"letter_url":347,"updated_at":348,"action_type":22,"case_status":86,"posted_date":349,"marcs_cms_no":350,"product_type":232,"closeout_date":351,"issuing_office":341,"recipient_name":352,"body_fetched_at":353,"delivery_method":332,"recipient_title":19,"reference_number":19,"action_taken_date":354,"medical_device_id":19,"response_letter_date":19},2483,[338,339,340,341,223,13,342,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":356,"raw":357,"subject":12,"body_html":361,"body_text":362,"firm_name":363,"letter_id":364,"created_at":124,"fei_number":19,"letter_url":365,"updated_at":366,"action_type":22,"case_status":23,"posted_date":367,"marcs_cms_no":368,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":369,"body_fetched_at":370,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":371,"medical_device_id":19,"response_letter_date":19},2798,[358,359,360,37,12,13,13,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-09T05:00:00Z\">03\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgw-food-usa-inc-624967-03092022\">GW FOOD USA Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Chong Hsin Cheng\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GW FOOD USA Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10928 Weaver Avenue, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South El Monte\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91733-2784\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 09, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 624967\u003C\u002Fp>\n\n\u003Cp>Dear Mr. David Chong Hsin Cheng:\u003C\u002Fp>\n\n\u003Cp>On November 30 through December 2, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of GW FOOD USA Inc., located at 10928 Weaver Ave., Suite C, South El Monte, CA 91733. We also conducted an inspection on May 7-8, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm\">https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on December 2, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003Cbr>\n\u003Cbr>\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods that you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Organic Soya \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Organic Soya \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Seaweed &amp; Fish Chip imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>During the most recent inspection, you provided records for one of your foreign suppliers, which you identified as \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You initially presented the records to FDA in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the close-out meeting, one of your staff members used Internet software to generate an English translation. However, the firm name on the translated documents is&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which does not match the name of any of the foreign suppliers covered in this inspection. The translated documents included a Standard Operating Procedure for Sanitation, Standard Operating Procedure for Warehousing Control, &amp; Equipment Management Procedure. We are unable to evaluate the adequacy of this response because you did not provide your review of these documents or how they would apply to your FSVP for any of your products.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>In addition, based on the information available to the agency, it appears you may meet the definition of a very small importer, as defined in 21 CFR 1.500. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Please provide an English translation of any records that you provide in a language other than English in order to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Lin Liu, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Mr. Lin Liu via email at lin.liu@fda.hhs.gov. Please reference CMS # 624967 on any documents or records you provide to us and in the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kathleen Turner, DVM\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDavid Chong Hsin Cheng\n\nRecipient Title\n\nGeneral Manager\n\nGW FOOD USA Inc.\n\n10928 Weaver Avenue, Suite C\n\nSouth El Monte, CA 91733-2784\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nMarch 09, 2022\n\nWARNING LETTER\n\nRe: CMS # 624967\n\nDear Mr. David Chong Hsin Cheng:\n\nOn November 30 through December 2, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of GW FOOD USA Inc., located at 10928 Weaver Ave., Suite C, South El Monte, CA 91733. We also conducted an inspection on May 7-8, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FFSMA\u002Fucm361902.htm.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on December 2, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any of the foods that you import, including:\n\nOrganic Soya (b)(4) and Organic Soya (b)(4) imported from (b)(4) located in (b)(4)\n\nSeaweed & Fish Chip imported from (b)(4) located in (b)(4)\n\nDuring the most recent inspection, you provided records for one of your foreign suppliers, which you identified as (b)(4) located in (b)(4). You initially presented the records to FDA in (b)(4). During the close-out meeting, one of your staff members used Internet software to generate an English translation. However, the firm name on the translated documents is (b)(4), located in (b)(4), which does not match the name of any of the foreign suppliers covered in this inspection. The translated documents included a Standard Operating Procedure for Sanitation, Standard Operating Procedure for Warehousing Control, & Equipment Management Procedure. We are unable to evaluate the adequacy of this response because you did not provide your review of these documents or how they would apply to your FSVP for any of your products.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nIn addition, based on the information available to the agency, it appears you may meet the definition of a very small importer, as defined in 21 CFR 1.500. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Please provide an English translation of any records that you provide in a language other than English in order to facilitate our review.\n\nPlease send your reply to Food and Drug Administration, Attention: Lin Liu, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Mr. Lin Liu via email at lin.liu@fda.hhs.gov. Please reference CMS # 624967 on any documents or records you provide to us and in the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nKathleen Turner, DVM\n\nProgram Division Director\n\nDivision of West Coast Imports","GW FOOD USA Inc.","gw-food-usa-inc-624967-03092022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgw-food-usa-inc-624967-03092022","2026-10-26T08:08:51.871585+00:00","2022-03-22","624967","David Chong Hsin Cheng","2026-08-20T02:05:07.477+00:00","2022-03-09",{"id":373,"raw":374,"subject":320,"body_html":378,"body_text":379,"firm_name":380,"letter_id":381,"created_at":382,"fei_number":19,"letter_url":383,"updated_at":164,"action_type":22,"case_status":23,"posted_date":384,"marcs_cms_no":385,"product_type":386,"closeout_date":19,"issuing_office":56,"recipient_name":19,"body_fetched_at":387,"delivery_method":388,"recipient_title":19,"reference_number":19,"action_taken_date":389,"medical_device_id":19,"response_letter_date":19},22104,[375,376,377,56,320,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-26T04:00:00Z\">10\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fong-tien-usa-llc-737352-10262026\">Ong Tien USA LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Ong Tien USA LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11209 Bellaire Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77072-2536\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ongtienlinhchi@gmail.com\"> ongtienlinhchi@gmail.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 26, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 737352\u003C\u002Fp>\u003Cp>To Ong Tien USA LLC:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fongtienlinhchi.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Additionally, FDA purchased “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên” from your website, but instead received a product labeled as “Sâm Xương Khớp Ông Tiên.” We have serious safety concerns about this product. FDA confirmed through laboratory analysis that your product labeled as “Sâm Xương Khớp Ông Tiên” contains piroxicam and dexamethasone phosphate. Piroxicam is a type of pain and inflammation reliever known as an NSAID. NSAIDs can increase the risk of serious heart problems, such as heart attack and stroke, and can cause serious gastrointestinal problems, such as bleeding, ulcers or life-threatening tears in the stomach or intestinal lining. Piroxicam can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects. Dexamethasone is a steroid medication commonly used to reduce inflammation. However, it can weaken the immune system, making it harder for the body to fight infections. It also can cause high blood sugar, muscle damage and mental health problems.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Fongtienlinhchi.com in April 2026. In addition, FDA attempted to purchase “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên” through your website, https:\u002F\u002Fongtienlinhchi.com, but instead received a product labeled as “Sâm Xương Khớp Ông Tiên.” Based on our review, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Further, “Sâm Xương Khớp Ông Tiên” is misbranded under 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(a), 301(d), and\u002For 505(a) of the FD&amp;C Act, 21 U.S.C. 331(a), 331(d), and\u002For 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website and product label, respectively, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fongtienlinhchi.com\u002Fproducts\u002Fong-tien-linh-chi:\u003C\u002Fp>\u003Cul>\u003Cli>“[D]esigned to relieve joint pain, reduce inflammation, and support musculoskeletal health. It enhances joint mobility, strengthens connective tissues, and promotes healing, providing relief from symptoms of gout, arthritis, and other joint-related issues.”\u003C\u002Fli>\u003Cli>“Relieves joint pain and back pain safely.”\u003C\u002Fli>\u003Cli>“Health Benefits\u003Cbr>o Support and disease prevention\u003Cbr>o Gout\u003Cbr>o Body aches\u003Cbr>o Osteoarthritis”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Sâm Xương Khớp Ông Tiên\u003C\u002Fu>\u003Cbr>On the product label:\u003C\u002Fp>\u003Cul>\u003Cli>“[G]out, joint pain, pain in the elderly, and general body aches.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fongtienlinhchi.com\u002Fproducts\u002Fsam-te-bao-goc-bao-tu-nam-linh-chi:\u003C\u002Fp>\u003Cul>\u003Cli>“Health Benefits\u003Cbr>o Joint and Back Pain Relief . . .\u003Cbr>o Anti-Inflammatory Effects . . .\u003Cbr>o Anti-Cancer and Anti-Tumor Properties”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and ““Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drugs product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>“Sâm Xương Khớp Ông Tiên” is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that in determining whether an article’s labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your “Sâm Xương Khớp Ông Tiên” product does not declare that it contains piroxicam or dexamethasone phosphate. As previously mentioned, FDA confirmed through laboratory analysis that your product contains piroxicam and dexamethasone phosphate. Consumers may purchase and use this product without knowing that it contains these potent pharmaceutical drug ingredients, which may cause serious harm or interact dangerously with other medications the consumer may be taking. The failure to disclose piroxicam and dexamethasone phosphate in the product labeling renders “Sâm Xương Khớp Ông Tiên” misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this misbranded drug product is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “737352” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nOng Tien USA LLC\n\n11209 Bellaire Blvd\n\nHouston, TX 77072-2536\n\nUnited States\n\nongtienlinhchi@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 26, 2026\nWARNING LETTER\nReference Number: 737352\nTo Ong Tien USA LLC:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Fongtienlinhchi.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAdditionally, FDA purchased “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên” from your website, but instead received a product labeled as “Sâm Xương Khớp Ông Tiên.” We have serious safety concerns about this product. FDA confirmed through laboratory analysis that your product labeled as “Sâm Xương Khớp Ông Tiên” contains piroxicam and dexamethasone phosphate. Piroxicam is a type of pain and inflammation reliever known as an NSAID. NSAIDs can increase the risk of serious heart problems, such as heart attack and stroke, and can cause serious gastrointestinal problems, such as bleeding, ulcers or life-threatening tears in the stomach or intestinal lining. Piroxicam can interact with other medications, especially other NSAID-containing products, and may significantly increase the risk of these serious side effects. Dexamethasone is a steroid medication commonly used to reduce inflammation. However, it can weaken the immune system, making it harder for the body to fight infections. It also can cause high blood sugar, muscle damage and mental health problems.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Fongtienlinhchi.com in April 2026. In addition, FDA attempted to purchase “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên” through your website, https:\u002F\u002Fongtienlinhchi.com, but instead received a product labeled as “Sâm Xương Khớp Ông Tiên.” Based on our review, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Further, “Sâm Xương Khớp Ông Tiên” is misbranded under 502(a) of the FD&C Act, 21 U.S.C. 352(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(a), 301(d), and\u002For 505(a) of the FD&C Act, 21 U.S.C. 331(a), 331(d), and\u002For 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website and product label, respectively, “Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and “Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nSâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên\nOn the webpage https:\u002F\u002Fongtienlinhchi.com\u002Fproducts\u002Fong-tien-linh-chi:\n“[D]esigned to relieve joint pain, reduce inflammation, and support musculoskeletal health. It enhances joint mobility, strengthens connective tissues, and promotes healing, providing relief from symptoms of gout, arthritis, and other joint-related issues.”\n“Relieves joint pain and back pain safely.”\n“Health Benefits\no Support and disease prevention\no Gout\no Body aches\no Osteoarthritis”\nSâm Xương Khớp Ông Tiên\nOn the product label:\n“[G]out, joint pain, pain in the elderly, and general body aches.”\nCao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi\nOn the webpage https:\u002F\u002Fongtienlinhchi.com\u002Fproducts\u002Fsam-te-bao-goc-bao-tu-nam-linh-chi:\n“Health Benefits\no Joint and Back Pain Relief . . .\no Anti-Inflammatory Effects . . .\no Anti-Cancer and Anti-Tumor Properties”\n“Sâm Xương Khớp Tế Bào Gốc Linh Chi Ông Tiên,” “Sâm Xương Khớp Ông Tiên,” and ““Cao Đông Trùng Hạ Thảo Tế Bào Gốc Linh Chi” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drugs product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nMisbranded Drug Violations\n“Sâm Xương Khớp Ông Tiên” is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that in determining whether an article’s labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your “Sâm Xương Khớp Ông Tiên” product does not declare that it contains piroxicam or dexamethasone phosphate. As previously mentioned, FDA confirmed through laboratory analysis that your product contains piroxicam and dexamethasone phosphate. Consumers may purchase and use this product without knowing that it contains these potent pharmaceutical drug ingredients, which may cause serious harm or interact dangerously with other medications the consumer may be taking. The failure to disclose piroxicam and dexamethasone phosphate in the product labeling renders “Sâm Xương Khớp Ông Tiên” misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\nThe introduction or delivery for introduction into interstate commerce of this misbranded drug product is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “737352” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration","Ong Tien USA LLC","ong-tien-usa-llc-737352-10262026","2026-11-10T01:02:16.121874+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fong-tien-usa-llc-737352-10262026","2026-11-03","737352","Drugs","2026-11-10T01:03:17.705+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-10-26",{"id":391,"raw":392,"subject":12,"body_html":397,"body_text":398,"firm_name":399,"letter_id":400,"created_at":184,"fei_number":19,"letter_url":401,"updated_at":402,"action_type":22,"case_status":23,"posted_date":403,"marcs_cms_no":404,"product_type":26,"closeout_date":19,"issuing_office":396,"recipient_name":405,"body_fetched_at":406,"delivery_method":192,"recipient_title":19,"reference_number":19,"action_taken_date":407,"medical_device_id":19,"response_letter_date":19},359,[393,394,395,396,12,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-23T04:00:00Z\">10\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmg-group-usa-718152-10232025\">MG GROUP USA\u003C\u002Fa>","Office of Inspections and Investigations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nunziata Di Nardo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MG GROUP USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>87 2nd St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harrison\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10528-4411\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 23, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 718152\u003C\u002Fp>\u003Cp>Dear Ms. Nunziata Di Nardo:\u003C\u002Fp>\u003Cp>On August 14, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of MG GROUP USA, located at 87 2nd St Harrison, NY 10528-4411We also conducted an inspection between February 8, 2023 through February 21, 2023 and September 9, 2024 through September16, 2024. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Despite providing a response to the 483a, you did not provide any documentation to show proof that you \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that you have developed FSVP’s for any of the foods you import.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>White Truffle Olive Oil from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Fresh Summer Truffles from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Fresh Black Truffles from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Spiridoula Dimopoulos, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Spiridoul.Dimopoulos@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Dimopoulos via email at Spiridoul.Dimopoulos@fda.hhs.gov. Please reference CMS # 718152 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Import\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nNunziata Di Nardo\n\nRecipient Title\n\nOwner\n\nMG GROUP USA\n\n87 2nd St\n\nHarrison, NY 10528-4411\n\nUnited States\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nOctober 23, 2025\nWARNING LETTER\nRE: CMS# 718152\nDear Ms. Nunziata Di Nardo:\nOn August 14, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of MG GROUP USA, located at 87 2nd St Harrison, NY 10528-4411We also conducted an inspection between February 8, 2023 through February 21, 2023 and September 9, 2024 through September16, 2024. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. Despite providing a response to the 483a, you did not provide any documentation to show proof that you (b)(4) and that you have developed FSVP’s for any of the foods you import.\nYour significant violations of the FSVP regulation are as follows:\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\nWhite Truffle Olive Oil from (b)(4) located in (b)(4)\nFresh Summer Truffles from foreign supplier (b)(4) located in (b)(4)\nFresh Black Truffles from foreign supplier (b)(4) located in (b)(4)\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Spiridoula Dimopoulos, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Spiridoul.Dimopoulos@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Dimopoulos via email at Spiridoul.Dimopoulos@fda.hhs.gov. Please reference CMS # 718152 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Import","MG GROUP USA","mg-group-usa-718152-10232025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmg-group-usa-718152-10232025","2026-10-26T08:09:24.471695+00:00","2026-01-27","718152","Nunziata Di Nardo","2026-08-19T07:16:54.962+00:00","2025-10-23",80,{"510k":410,"classification":411,"enforcement":412,"event":413,"event_backfill":414,"pma":415,"warning_letter":416},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]